
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-70b9163a.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-ec2bc71e.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Lung cancer in never smokers—the East Asian experience - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="8CB1E11871B29BF305E118001FD93377.m_1" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="dns-prefetch" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <link rel="preconnect" href="https://code.jquery.com" />
    <meta name="ncbi_domain" content="tlcr">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6131183/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Translational Lung Cancer Research">
<meta name="citation_title" content="Lung cancer in never smokers—the East Asian experience">
<meta name="citation_author" content="Fei Zhou">
<meta name="citation_author_institution" content="Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China">
<meta name="citation_author" content="Caicun Zhou">
<meta name="citation_author_institution" content="Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China">
<meta name="citation_publication_date" content="2018 Aug">
<meta name="citation_volume" content="7">
<meta name="citation_issue" content="4">
<meta name="citation_firstpage" content="450">
<meta name="citation_doi" content="10.21037/tlcr.2018.05.14">
<meta name="citation_pmid" content="30225210">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC6131183/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC6131183/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC6131183/pdf/tlcr-07-04-450.pdf">
<meta name="description" content="Approximately one third of all lung cancer patients in East Asia are never-smokers. Furthermore, the proportion of lung cancer in never smokers (LCINS) has been increasing over time. Never-smokers are more often diagnosed with adenocarcinoma in East ...">
<meta name="og:title" content="Lung cancer in never smokers—the East Asian experience">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Approximately one third of all lung cancer patients in East Asia are never-smokers. Furthermore, the proportion of lung cancer in never smokers (LCINS) has been increasing over time. Never-smokers are more often diagnosed with adenocarcinoma in East ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC6131183/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            
                <a class="ncbi-header__logo-container" href="/">
                    <img alt="
                                  PMC home page
                              "
                         class="ncbi-header__logo-image"
                         src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" />
                </a>
            

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-testid="searchPanel"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      aria-describedby="search-field-desktop-navigation-help-text"
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only"
                           data-testid="label"
                           for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           data-testid="textInput"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    data-testid="button"
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  role="search">
                <label class="usa-sr-only" for="search-field">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="search" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column pmc-header__search__form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search" type="search" name="term" data-autocomplete-url="/search/autocomplete/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <ul class="pmc-header__search__menu">
                <li>
                    <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search">
                        Advanced Search
                    </a>
                </li>
                <li>
                    
                        <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                            Journal List
                        </a>
                    
                </li>
                <li>
                    
                        <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                        data-ga-label="user guide">
                            User Guide
                        </a>
                    
                </li>
            </ul>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="6131183">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.21037/tlcr.2018.05.14"
                                class="usa-link display-flex"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/tlcr-07-04-450.pdf"
                                     class="usa-link display-flex"
                                     role="button"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                                class="usa-button usa-button--unstyled collections-dialog-trigger collections-button display-flex collections-button-empty"
                                 aria-label="Save article in MyNCBI collections."
                                  data-ga-category="actions"
                                  data-ga-action="click"
                                  data-ga-label="collections_button_mobile"
                                  data-collections-open-dialog-enabled="false"
                                  data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC6131183%2F%23open-collections-dialog"
                                  data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/6131183/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/6131183/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex">
                         <button
                                 type="button"
                                 class="usa-button usa-button--unstyled display-flex"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC6131183/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-tlcr.gif" alt="Translational Lung Cancer Research logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Translational Lung Cancer Research" title="Link to Translational Lung Cancer Research" shape="default" href="http://www.tlcr.org/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Transl Lung Cancer Res</button></div>. 2018 Aug;7(4):450–463. doi: <a href="https://doi.org/10.21037/tlcr.2018.05.14" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.21037/tlcr.2018.05.14</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Transl%20Lung%20Cancer%20Res%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Transl%20Lung%20Cancer%20Res%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Transl%20Lung%20Cancer%20Res%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Transl%20Lung%20Cancer%20Res%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Lung cancer in never smokers—the East Asian experience</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhou%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Fei Zhou</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Fei Zhou</span></h3>
<div class="p">
<sup>1</sup>Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhou%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Fei Zhou</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhou%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Caicun Zhou</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Caicun Zhou</span></h3>
<div class="p">
<sup>1</sup>Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhou%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Caicun Zhou</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff1">
<sup>1</sup>Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China</div>
<div class="author-notes p">
<div class="fn" id="afn1"><p><em>Contributions:</em> (I) Conception and design: All authors; (II) Administrative support: All authors; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.</p></div>
<div class="fn" id="cor1">
<sup>✉</sup><p class="display-inline"><em>Correspondence to:</em> Prof. Caicun Zhou. Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, No 507 Zhengmin Road, Yangpu District, Shanghai 200433, China. Email: <span>caicunzhoudr@163.com</span>.</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2018 Jan 1; Accepted 2018 May 17; Issue date 2018 Aug.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>2018 Translational Lung Cancer Research. All rights reserved.</div>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC6131183  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/30225210/" class="usa-link">30225210</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>Approximately one third of all lung cancer patients in East Asia are never-smokers. Furthermore, the proportion of lung cancer in never smokers (LCINS) has been increasing over time. Never-smokers are more often diagnosed with adenocarcinoma in East Asia, a subtype largely defined by oncogenic drivers. In this subgroup of patients, as high as 90% of patients have been found to harbor well-known oncogenic mutations and can be successfully managed with targeted therapies inhibiting specific oncogenic mutant kinases. EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment has been the most important targeted therapy in lung adenocarcinoma from East Asian never-smokers as approximately 70% of these patients have the opportunity to receive EGFR-TKI treatment. Lung squamous cell carcinoma (SQCC) and small cell lung cancer (SCLC) are two common histologic types of smoking-related non-small cell lung cancer (NSCLC). The proportion of never-smokers with SQCC and SCLC in East Asian patients seems to be higher than that in Caucasian patients. Recent studies also suggest that lung SQCC and SCLC in never-smokers may be distinct subtypes. Therefore, better understanding of the biologic characteristics of these subtypes of patients may provide new insights for the treatment. In this review, we will provide an overview of East Asian experience in the treatment of advanced, never-smoking lung cancer, focusing on etiologic factors in the development of LCINS, targeted therapy for never-smokers with adenocarcinoma, distinct characteristics of never-smokers with lung SQCC and SCLC, and the role of immunotherapy in never-smokers with NSCLC.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords: </strong> Never-smokers, East Asian, targeted therapy, immunotherapy, lung cancer</p></section></section><section id="sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p>Lung cancer is the leading cause of cancer-related deaths in China and accounted for an estimated 610,000 deaths in 2015 (<a href="#r1" class="usa-link" aria-describedby="r1">1</a>). The majority of lung cancers are thought to be attributed to direct tobacco exposure. However, approximately 10% to 25% of all lung cancers occur in never smokers (<a href="#r2" class="usa-link" aria-describedby="r2">2</a>,<a href="#r3" class="usa-link" aria-describedby="r3">3</a>), defined as those who smoked fewer than 100 cigarettes during their lifetime. Notably, epidemiologic studies reveal that the proportion of lung cancer in never smokers (LCINS) is higher in East Asia, including China, Japan, Mongolia, North Korea, and South Korea, and approximately one third of all lung cancer patients are LCINS [39.7% in China (our unpublished data), 38% in South Korea (<a href="#r4" class="usa-link" aria-describedby="r4">4</a>) and 32.8% in Japan (<a href="#r5" class="usa-link" aria-describedby="r5">5</a>)]. The high proportion of LCINS is mainly due to low smoking prevalence of East Asian females with lung cancer [9.9% in South Korea, 17–25.6% in Japan, 28.3% in Hong Kong, 6.4% in Taiwan, and 5.2% in China (our unpublished data)], which was significantly lower than that in Caucasian female patients (ranging from 53% to 91%) (<a href="#r4" class="usa-link" aria-describedby="r4">4</a>-<a href="#r10" class="usa-link" aria-describedby="r10">10</a>). Meanwhile, the smoking rate of male patients with lung cancer is similar between East Asia and Western countries (<a href="#f1" class="usa-link"><em>Figure 1</em></a>) (<a href="#r4" class="usa-link" aria-describedby="r4">4</a>-<a href="#r10" class="usa-link" aria-describedby="r10">10</a>).The proportion of LCINS has been increasing over time (<a href="#r5" class="usa-link" aria-describedby="r5">5</a>). Although the reason remains unknown, a better understanding of the epidemiologic and biologic characteristics of never-smokers has become increasingly important.</p>
<figure class="fig xbox font-sm" id="f1"><h3 class="obj_head">Figure 1.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e764/6131183/add8e7a76484/tlcr-07-04-450-f1.jpg" loading="lazy" height="467" width="669" alt="Figure 1"></p>
<div class="p text-right font-secondary"><a href="figure/f1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Smoking prevalence of lung cancer patients by gender in East Asia, Europe and USA.</p></figcaption></figure><p>Never-smokers in East Asians are more often diagnosed with adenocarcinoma, a subtype largely defined by oncogenic drivers (<a href="#r11" class="usa-link" aria-describedby="r11">11</a>). The proportion of never-smokers in lung squamous cell carcinoma (SQCC) and small cell lung cancer (SCLC) is also higher among East Asian patients than in non-Asian patients (<a href="#r12" class="usa-link" aria-describedby="r12">12</a>,<a href="#r13" class="usa-link" aria-describedby="r13">13</a>). Therefore, oncologists in East Asia have more opportunities to treat never-smoking patients with non-small cell lung cancer (NSCLC) in clinical practice. In this review, we will provide an overview of the East Asian experience in the treatment of advanced, never-smoking lung cancer.</p></section><section id="sec2"><h2 class="pmc_sec_title">Etiologic factors in the development of LCINS</h2>
<p>Given the dominant role of tobacco exposure in the development of lung cancer, risk factors that contribute the pathogenesis of lung cancer have also been comprehensively investigated. The role of environmental tobacco exposure in the development of LCINS has been widely studied. A recent pooled study from 18 case-control studies in the International Lung Cancer Consortium, including 766 cases and 1,954 control who were never-smokers from Asian, has demonstrated that exposure to second-hand smoke is associated with an increased risk of lung cancer in never-smokers [odds ratio (OR) =1.31, 95% confidence interval (CI), 1.17–1.47) (<a href="#r14" class="usa-link" aria-describedby="r14">14</a>). Moreover, the strongest association was observed in SCLC (OR =1.26, 95% CI: 1.10–1.44 for adenocarcinoma; OR =1.41, 95% CI: 0.99–1.99 for SQCC; OR =1.48, 95% CI: 0.89–2.45 for large cell lung cancer; OR =3.09, 95% CI: 1.62–5.89 for SCLC) (<a href="#r14" class="usa-link" aria-describedby="r14">14</a>). Based on data from the Global Adult Tobacco Survey (GATS) conducted from December 2009 to March 2010 (<a href="#r15" class="usa-link" aria-describedby="r15">15</a>,<a href="#r16" class="usa-link" aria-describedby="r16">16</a>), the prevalence of current smokers in adult age more than 15 years old was 28.1% in China, with an estimated more than 300 million current smokers. Due to lack of effective strategies for tobacco control for the public, exposure to second-hand smoke both at home and the workplace may play an important role in the development of LCINS in China.</p>
<p>Another important factor associated with an increased risk of LCINS is exposure to cooking fumes, as several case-control studies have identified cooking oil fumes as a risk factor for lung cancer among Chinese never-smoking women (<a href="#r17" class="usa-link" aria-describedby="r17">17</a>-<a href="#r20" class="usa-link" aria-describedby="r20">20</a>). A recent meta-analysis including 13 studies, with a total of 3,596 lung cancer women and 6,082 healthy controls also validated the positive relationship between cooking oil fume exposure and lung cancer among Chinese never-smoking women, with a risk ratio (RR) of 1.74 (95% CI: 1.57–1.94) (<a href="#r21" class="usa-link" aria-describedby="r21">21</a>).</p>
<p>Other factors that play a role in the etiology of LCINS in non-smokers from East Asia also include inherited genetic susceptibility (<a href="#r22" class="usa-link" aria-describedby="r22">22</a>-<a href="#r24" class="usa-link" aria-describedby="r24">24</a>), occupational and environmental exposure (<a href="#r25" class="usa-link" aria-describedby="r25">25</a>), hormonal factors (<a href="#r26" class="usa-link" aria-describedby="r26">26</a>), pre-existing lung diseases (<a href="#r27" class="usa-link" aria-describedby="r27">27</a>-<a href="#r30" class="usa-link" aria-describedby="r30">30</a>), suggesting that the etiopathogenesis of LCINS is a complex process with multiple risk factors involved.</p></section><section id="sec3"><h2 class="pmc_sec_title">Lung adenocarcinoma in never-smoking East Asian: a subtype largely defined by oncogenic drivers</h2>
<p>Considerable molecular epidemiologic studies have demonstrated that lung adenocarcinoma from East Asian never-smokers is a distinct subtype that can be largely defined by targetable oncogenic drivers (<a href="#r11" class="usa-link" aria-describedby="r11">11</a>,<a href="#r31" class="usa-link" aria-describedby="r31">31</a>-<a href="#r35" class="usa-link" aria-describedby="r35">35</a>) (<a href="#f2" class="usa-link"><em>Figures 2,3</em></a>). In this subgroup of patients, as high as 90% of patients have been found to harbor well-known oncogenic mutations and LCINS seems to be substantially driven by a single gene (<a href="#r11" class="usa-link" aria-describedby="r11">11</a>,<a href="#r32" class="usa-link" aria-describedby="r32">32</a>). On the other side, smoking-related lung cancer is a more distinct entity, with higher mutation burden, somatic single-nucleotide variations (SNVs) and higher frequency of C:G→A:T transversions (<a href="#r39" class="usa-link" aria-describedby="r39">39</a>). Smoking status may also have an impact on <em>EGFR</em> mutations, the frequency of <em>EGFR</em> mutations ranged from 22.0% to 43.5% in Chinese smokers with adenocarcinoma (<a href="#r40" class="usa-link" aria-describedby="r40">40</a>,<a href="#r41" class="usa-link" aria-describedby="r41">41</a>). Therefore, targeted therapy inhibiting oncogenic mutant kinases plays a pivotal role for the treatment of lung adenocarcinoma in never-smoking East Asians.</p>
<figure class="fig xbox font-sm" id="f2"><h3 class="obj_head">Figures 2.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e764/6131183/f3080375c427/tlcr-07-04-450-f2.jpg" loading="lazy" height="697" width="768" alt="Figures 2"></p>
<div class="p text-right font-secondary"><a href="figure/f2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Pooled analysis of frequency of driver genes in adenocarcinoma from 8 studies, including 2,126 East Asian Never Smokers (<a href="#r11" class="usa-link" aria-describedby="r11">11</a>,<a href="#r31" class="usa-link" aria-describedby="r31">31</a>-<a href="#r33" class="usa-link" aria-describedby="r33">33</a>,<a href="#r35" class="usa-link" aria-describedby="r35">35</a>-<a href="#r38" class="usa-link" aria-describedby="r38">38</a>).</p></figcaption></figure><figure class="fig xbox font-sm" id="f3"><h3 class="obj_head">Figure 3.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e764/6131183/7e127b0752fa/tlcr-07-04-450-f3.jpg" loading="lazy" height="765" width="676" alt="Figure 3"></p>
<div class="p text-right font-secondary"><a href="figure/f3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Distribution of common driver genes in never-smokers with adenocarcinoma in cases from Shanghai Pulmonary Hospital, from 2012 to 2016.</p></figcaption></figure><section id="sec4"><h3 class="pmc_sec_title">EGFR sensitizing mutations</h3>
<p><em>EGFR</em> sensitizing mutation is the most common driver gene found in never-smoker adenocarcinoma from East Asia, constituting 60–78% of this subgroup (<a href="#r11" class="usa-link" aria-describedby="r11">11</a>,<a href="#r32" class="usa-link" aria-describedby="r32">32</a>,<a href="#r35" class="usa-link" aria-describedby="r35">35</a>-<a href="#r37" class="usa-link" aria-describedby="r37">37</a>). Robust evidence has identified <em>EGFR</em> sensitizing mutation as the most relevant predictor of response to the <em>EGFR</em> tyrosine kinase inhibitors (EGFR-TKIs) (<a href="#r42" class="usa-link" aria-describedby="r42">42</a>-<a href="#r44" class="usa-link" aria-describedby="r44">44</a>). Several randomized phase III trials have consistently demonstrated that gefitinib, erlotinib and afatinib are more effective in terms of objective response rate (ORR) and progression-free survival (PFS), and better tolerated than standard platinum-based doublet chemotherapy in advanced NSCLC patients harboring <em>EGFR</em> activating mutation. Among these trials, IPASS, LUX-LUNG 6 trial was conducted in Asian (<a href="#r45" class="usa-link" aria-describedby="r45">45</a>,<a href="#r46" class="usa-link" aria-describedby="r46">46</a>), First-SIGNAL trial was conducted in South Korea (<a href="#r47" class="usa-link" aria-describedby="r47">47</a>), OPTIMAL, ENSURE, and CONVINCE trial were conducted in China (<a href="#r48" class="usa-link" aria-describedby="r48">48</a>-<a href="#r50" class="usa-link" aria-describedby="r50">50</a>), WJTOG3405 and NEJ002 trial were conducted in Japan (<a href="#r51" class="usa-link" aria-describedby="r51">51</a>,<a href="#r52" class="usa-link" aria-describedby="r52">52</a>). To date, EGFR-TKI treatment has been the most important targeted therapy in lung adenocarcinoma from East Asia never-smokers as approximately 70% of these patients have the opportunity to receive EGFR-TKI treatment. Of note, although the above-mentioned trials did not enroll <em>EGFR</em>-mutant patients based on histologic type and smoking status, most of the enrolled patients (ranging from 87% to 100%) presented with adenocarcinoma histology. Furthermore, of the 1,416 patients enrolled in the six trials that only included <em>EGFR</em>-mutant patients (LUX-LUNG 6, OPTIMAL, ENSURE, CONVINCE, WJTOG3405 and NEJ002 trial), only 27.9% (395/1,416) were former or current smokers. A recent meta-analysis revealed that smoking status may have an adverse impact on the PFS benefit of EGFR-TKI treatment (pooled HR for PFS of never-smokers, 0.32, 95% CI: 0.27–0.37, treatment-smoking interaction P=0.02). However, current or former smokers can also derive PFS benefit from EGFR-TKI treatment (pooled HR for PFS, 0.50, 95% CI: 0.40–0.63) (<a href="#r53" class="usa-link" aria-describedby="r53">53</a>).</p>
<p>Although initial response is often tremendous, most patients, if not all, eventually become resistance to EGFR-TKIs. Prospective trials have investigated the role of continuation of EGFR-TKIs beyond progression (<a href="#r54" class="usa-link" aria-describedby="r54">54</a>-<a href="#r57" class="usa-link" aria-describedby="r57">57</a>). ASPIRATION trial was a phase 2, open-label, single-arm study conducted in Hong Kong, South Korea, Taiwan, and Thailand, including patients with stage IV, <em>EGFR</em>-mutant NSCLC (<a href="#r54" class="usa-link" aria-describedby="r54">54</a>). Of the 207 enrolled patients, 72.9% (151/207) were never-smokers and 97.1% (201/207) presented with adenocarcinoma histology. ASPIRATION trial demonstrated that continuing erlotinib therapy beyond progression result in a 3.1-month improvement in PFS, suggesting continuing erlotinib therapy beyond progression is feasible in Asian patients. IMPRESS trial was a phase 3 randomized trial that compared the continuation of gefitinib plus chemotherapy with placebo plus chemotherapy in patients with <em>EGFR</em> mutation-positive advanced NSCLC after failure of first-line gefitinib (<a href="#r56" class="usa-link" aria-describedby="r56">56</a>). However, continuation of gefitinib in combination with platinum-based chemotherapy did not prolong PFS as compared with chemotherapy alone (median PFS: 5.4 <em>vs.</em> 5.4 months, HR =0.86, 95% CI: 0.65–1.13, P=0.27) (<a href="#r56" class="usa-link" aria-describedby="r56">56</a>). Recent updated OS and biomarker analyses demonstrated that continuation of gefitinib plus chemotherapy had a detrimental effect on OS when compared with chemotherapy alone (median OS, 13.4 <em>vs.</em> 19.5 months, HR =1.44, 95% CI: 1.07–1.94; P=0.016) (<a href="#r57" class="usa-link" aria-describedby="r57">57</a>). Furthermore, the detriment effect was significantly shown in patients with T790M mutation-positive plasma samples (HR =1.49, 95% CI: 1.02–2.21, P=0.0432) (<a href="#r57" class="usa-link" aria-describedby="r57">57</a>). IMPRESS trial suggested that platinum-based doublet chemotherapy remains the standard of care when acquired resistance develops and the detrimental effect of continuation of gefitinib may be driven by T790M-positive status. Our recent retrospective study also showed that patients may derive modest benefit from continuation of gefitinib in T790M mutation-negative tumors (<a href="#r58" class="usa-link" aria-describedby="r58">58</a>).</p>
<p>The emergence of T790M secondary mutations at exon 20 remains the dominant cause of acquired resistance to EGFR-TKIs. T790M mutations occur in about half of acquired resistant cases in East Asian patients (<a href="#r59" class="usa-link" aria-describedby="r59">59</a>-<a href="#r61" class="usa-link" aria-describedby="r61">61</a>). Furthermore, T790M mutations is also the major acquired resistance mechanism of afatinib in East Asian patients, presenting in 47.6% (20/42) acquired resistant cases (<a href="#r62" class="usa-link" aria-describedby="r62">62</a>). Osimertinib (AZD9291) is an oral, potent, irreversible EGFR-TKI selective for both <em>EGFR</em> sensitizing mutations and T790M resistance mutations. Serial trials have investigated the efficacy of osimertinib in patients with T790M resistance mutations, with an ORR of 61% to 70% and median PFS of 9.6 to 12.3 months (<a href="#r63" class="usa-link" aria-describedby="r63">63</a>-<a href="#r65" class="usa-link" aria-describedby="r65">65</a>). AURA3 trial was a randomized, international, open-label, phase 3 trial that compared osimertinib with platinum-based therapy plus pemetrexed in T790M-positive patients (<a href="#r66" class="usa-link" aria-describedby="r66">66</a>). Osimertinib resulted in a significant improvement in ORR (71% <em>vs.</em> 31%, P&lt;0.001) and PFS (10.1 <em>vs.</em> 4.4 months; HR =0.30, 95% CI: 0.23–0.41, P&lt;0.001) when compared with standard chemotherapy. AURA17 was an open-label, single-arm, phase II study that evaluated the safety and efficacy of osimertinib in East Asian T790M-positive patients (<a href="#r67" class="usa-link" aria-describedby="r67">67</a>). Of the enrolled 171 patients, the ORR was 63% and median PFS was 9.7 months, which was consistent with the results observed from global data. To date, osimertinib has been approved for patients with T790M resistance mutations after failure of first- or second-generation EGFR-TKIs in China, Japan and South Korea.</p></section><section id="sec5"><h3 class="pmc_sec_title">ALK/ROS1/RET rearrangement</h3>
<p>Chromosomal rearrangement involving receptor tyrosine kinase (RTK) in lung cancer was first discovered in 2007 and currently rearrangements in three major RTKs have been identified as therapeutic targets in NSCLC.</p>
<section id="sec6"><h4 class="pmc_sec_title">ALK</h4>
<p><em>ALK</em> rearrangement defines another distinct subtype of patients with NSCLC, accounting for about 5% of all NSCLC cases (<a href="#r68" class="usa-link" aria-describedby="r68">68</a>). In never-smoker adenocarcinoma from East Asian, the frequency of <em>ALK</em> rearrangement range from 4.95% to 9.6% (<a href="#r11" class="usa-link" aria-describedby="r11">11</a>,<a href="#r31" class="usa-link" aria-describedby="r31">31</a>-<a href="#r35" class="usa-link" aria-describedby="r35">35</a>,<a href="#r69" class="usa-link" aria-describedby="r69">69</a>), which was similar with that in Caucasian. Crizotinib is an oral small-molecule TKI of <em>ALK</em>, <em>MET</em>, and <em>ROS1</em> kinases and has been approved for the first-line treatment of advanced <em>ALK</em>-rearranged NSCLC based on the results from PROFILE1014 trial (<a href="#r70" class="usa-link" aria-describedby="r70">70</a>). Nishio <em>et al.</em> recently reported a post-hoc analysis of the safety and efficacy of crizotinib in Asian populations from two global phase III trials (PROFILE1007 and PROFILE1014) (<a href="#r71" class="usa-link" aria-describedby="r71">71</a>). Consistent with the observations of overall patient populations, crizotinib also demonstrated better PFS (previously treated: 7.7 <em>vs.</em> 3.0 months, HR =0.49, 95% CI: 0.37–0.64, P&lt;0.001; previously untreated: 13.6 <em>vs.</em> 7.0 months, HR =0.44, 95% CI: 0.30–0.65, P&lt;0.001) and ORR (previously treated:75% <em>vs.</em> 22%, P&lt;0.05; previously untreated: 70% <em>vs.</em> 54%, P&lt;0.05) <em>vs.</em> chemotherapy both in previously treated and untreated Asian patients with <em>ALK</em>-positive NSCLC. The safety profile and efficacy were similar between Asian patients and non-Asian patients. PROFILE1029 trial was a randomized, phase 3 trial that compared crizotinib with platinum-based therapy plus pemetrexed in Chinese and Asian patients with <em>ALK</em>-positive tumors (<a href="#r72" class="usa-link" aria-describedby="r72">72</a>). The median PFS (11.1 months) and ORR (88%) were consistent with that observed in the PROFILE 1014 trial. To date, crizotinib has been proved as standard first-line therapy for patients with <em>ALK</em>-positive NSCLC in China, Japan and South Korea. Alectinib is a highly selective <em>ALK</em> inhibitor with high brain-penetrant that has shown high anti-tumor activity both in <em>ALK</em> inhibitor-naïve and crizotinib-resistant patients (<a href="#r73" class="usa-link" aria-describedby="r73">73</a>-<a href="#r75" class="usa-link" aria-describedby="r75">75</a>). J-ALEX trial was a randomized, open-label, phase 3 trial comparing alectinib with crizotinib in Japanese patients with previously crizotinib-naive, advanced <em>ALK</em>-positive NSCLC (<a href="#r76" class="usa-link" aria-describedby="r76">76</a>). J-ALEX trial showed the superiority of alectinib over crizotinib in terms of PFS (not reached <em>vs.</em> 10.2 months, HR =0.34, 99.7% CI: 0.17–0.71, P&lt;0.001). Dose interruptions due to adverse events were also significantly reduced with use of alectinib as compared with crizotinib (29% <em>vs.</em> 74%). The results of J-ALEX trial were further confirmed in ALEX trial and suggested the superiority of alectinib over crizotinib both in Asian and non-Asian <em>ALK</em>-positive NSCLC (<a href="#r77" class="usa-link" aria-describedby="r77">77</a>).</p></section><section id="sec7"><h4 class="pmc_sec_title">ROS1</h4>
<p><em>ROS1</em> is another RTK that shares extensive amino acid sequence homology with <em>ALK</em>. Clinical characteristics of patients with <em>ROS1</em> rearrangement are similar to those observed in patients with <em>ALK</em>-rearranged NSCLC (<a href="#r78" class="usa-link" aria-describedby="r78">78</a>,<a href="#r79" class="usa-link" aria-describedby="r79">79</a>). Although <em>ROS1</em> rearrangement was predominantly identified in never-smokers with adenocarcinoma, the alteration has also been found in patient with SQCC (<a href="#r80" class="usa-link" aria-describedby="r80">80</a>), adenosquamous (<a href="#r81" class="usa-link" aria-describedby="r81">81</a>,<a href="#r82" class="usa-link" aria-describedby="r82">82</a>), adenocarcinoma/SCLC (<a href="#r83" class="usa-link" aria-describedby="r83">83</a>), and even large cell carcinoma (<a href="#r84" class="usa-link" aria-describedby="r84">84</a>). Generally, the frequency rate of <em>ROS1</em> rearrangement was very low, with a prevalence ranging from 1% to 2% in Asian patients. Results from a phase I study (PROFILE1001) demonstrated that crizotinib was highly active in patients with <em>ROS1</em>-rearranged NSCLC; 72% (36/50) of enrolled patients responded to crizotinib and the PFS was amazing 19.2 months (<a href="#r85" class="usa-link" aria-describedby="r85">85</a>). Recently, second-generation <em>ALK</em>/<em>ROS1</em> inhibitor (ceritinib) (<a href="#r86" class="usa-link" aria-describedby="r86">86</a>), third-generation <em>ALK</em>/<em>ROS1</em> inhibitor (lorlatinib) (<a href="#r87" class="usa-link" aria-describedby="r87">87</a>) and multitarget TKIs (entrectinib and cabozantinib) (<a href="#r88" class="usa-link" aria-describedby="r88">88</a>,<a href="#r89" class="usa-link" aria-describedby="r89">89</a>) also demonstrated potent activity in patients with <em>ROS1</em>-rearranged NSCLC. In a large East Asian phase II study of crizotinib, the ORR was 69% and median PFS was 13.4 months in 127 patients with <em>ROS1</em>-rearranged NSCLC (<a href="#r90" class="usa-link" aria-describedby="r90">90</a>). In a South Korean phase II study, 32 patients with <em>ROS1</em>-rearranged NSCLC were treated with ceritinib (<a href="#r86" class="usa-link" aria-describedby="r86">86</a>). The ORR was 62% and median PFS was 9.3 months for all patients and 19.3 months for crizotinib-naïve patients.</p>
<p>Approximately 1% of lung adenocarcinoma are driven by oncogenic <em>RET</em> rearrangements (<a href="#r91" class="usa-link" aria-describedby="r91">91</a>). <em>RET</em>-rearranged tumors are commonly found in young never-smokers with a solid-predominant subtype of adenocarcinoma, constituting 1.4% of NSCLC and 1.7% of adenocarcinoma in Chinese patients (<a href="#r91" class="usa-link" aria-describedby="r91">91</a>). Consistently, the identified <em>RET</em>-rearranged patients in our previous study were all never-smokers (<a href="#r92" class="usa-link" aria-describedby="r92">92</a>). Independent investigators have evaluated the role of multikinase <em>RET</em> inhibitors, such as cabozantinib and vandetanib, in <em>RET</em>-rearranged NSCLC (<a href="#r93" class="usa-link" aria-describedby="r93">93</a>-<a href="#r95" class="usa-link" aria-describedby="r95">95</a>). Yoh <em>et al.</em> recently reported the activity of vandetanib in 19 patients with <em>RET</em>-rearranged Japanese NSCLC in a phase II trial (<a href="#r94" class="usa-link" aria-describedby="r94">94</a>). The ORR, median PFS, and median OS in overall patients were 47%, 4.7 months, and 11.1 months. Of note, the CCDC6-<em>RET</em> subtype showed a higher sensitivity to vandetanib than did the KIF5B-<em>RET</em> subtype [ORR: 20% (2/10) <em>vs.</em> 83% (5/6); median PFS: 2.9 <em>vs.</em> 8.3 months; median OS: 11.1 months <em>vs.</em> not reached] (<a href="#r94" class="usa-link" aria-describedby="r94">94</a>). GLORY (the Global, Multicenter RET Registry) was the largest single database of patients with <em>RET</em>-rearranged lung cancers (<a href="#r96" class="usa-link" aria-describedby="r96">96</a>). When the data was carried out, 165 patients with <em>RET</em>-rearranged NSCLC from 29 centers across Europe, Asia, and the USA were accrued. Of those, 53 patients were treated with a <em>RET</em> inhibitor. The ORR, median PFS, and median OS were 26%, 2.3 months and 6.8 months, respectively. Regarding specific <em>RET</em> inhibitors, the ORR of cabozantinib, vandetanib, and sunitinib was 37%, 18%, and 22%, median PFS was 3.6, 2.9, and 2.2 months and median OS was 4.9, 10.2 and 6.8 months, respectively. Notably, the ORR and PFS or OS were not statistically significant different by various fusion subtypes (KIF5B <em>vs.</em> other partner) (<a href="#r96" class="usa-link" aria-describedby="r96">96</a>).</p>
<p>In summary, the epidemiologic and clinical characteristics of East Asian patients with <em>ALK/ROS1/RET</em> rearrangements were similar with those of Caucasian patients. Although clinically meaningful benefit was seen with <em>RET</em> inhibition therapy in both Asian and non-Asian patients, its activity was lower than those treated with <em>ALK</em> or <em>ROS1</em> inhibitors in patient with <em>ALK</em> or <em>ROS1</em> rearrangements. Multikinase inhibitors might not be the most effective strategy for this subtype of patients and highly <em>RET</em>-specific TKIs are needed.</p></section></section><section id="sec8"><h3 class="pmc_sec_title">MET 14 exon (METex14) skipping</h3>
<p><em>METex14</em> skipping has been recently identified as a rare oncogenic alteration in NSCLC (<a href="#r97" class="usa-link" aria-describedby="r97">97</a>), with an overall frequency of 2.7–3.0% in Caucasian patients (<a href="#r97" class="usa-link" aria-describedby="r97">97</a>,<a href="#r98" class="usa-link" aria-describedby="r98">98</a>). Among 795 East Asian NSCLC patients, the prevalence of METex14 skipping was 2.1% (17/795) (<a href="#r99" class="usa-link" aria-describedby="r99">99</a>). Of 45 patients with quintuple-negative lung adenocarcinoma (<em>EGFR/KRAS/ALK/ROS1/RET</em> negative), 37.8% (17/45) of patients had METex14 skipping. The incidence of never-smokers in patients with METex14 skipping (41.2%) was significantly lower than that in patients with <em>EGFR</em> mutations or <em>ROS1</em> rearrangements (<a href="#r99" class="usa-link" aria-describedby="r99">99</a>). In another study including 1,296 Chinese patients with NSCLC, METex14 skipping occurred in 1% (12/1,296) of all NSCLC cases (<a href="#r100" class="usa-link" aria-describedby="r100">100</a>). Of these cases, 10 were with adenocarcinoma histology, 1 with adenosquamous, and 1 with SQCC. Among METex14 skipping adenocarcinoma, 50% were never-smokers. The prevalence of METex14 skipping in East Asian patients (1% to 2.1%) seemed to a bit lower than that in Caucasian patients (<a href="#r38" class="usa-link" aria-describedby="r38">38</a>,<a href="#r98" class="usa-link" aria-describedby="r98">98</a>,<a href="#r100" class="usa-link" aria-describedby="r100">100</a>). Preclinical data and case reports suggested that patients with METex14 skipping can derive clinical benefit from MET inhibitors (crizotinib and INC280) (<a href="#r97" class="usa-link" aria-describedby="r97">97</a>,<a href="#r101" class="usa-link" aria-describedby="r101">101</a>). However, in two cases of Chinese patients with METex14 skipping treated with crizotinib, 1 patients responded to crizotinib with a PFS of 9 months and the other one experienced disease progression only 1 month later, mainly due to co-existing with Kras mutations (<a href="#r100" class="usa-link" aria-describedby="r100">100</a>).</p></section><section id="sec9"><h3 class="pmc_sec_title">HER2 mutations</h3>
<p><em>HER2</em> is a member of the <em>EGFR</em> family of RTKs, which also includes <em>EGFR</em> (HER1), <em>HER3</em> and <em>HER4</em>. In the Chinese population, the prevalence of <em>HER2</em> mutations ranged from 2.4% to 5.94%, a little more common than Caucasian population (<a href="#r11" class="usa-link" aria-describedby="r11">11</a>,<a href="#r32" class="usa-link" aria-describedby="r32">32</a>,<a href="#r35" class="usa-link" aria-describedby="r35">35</a>,<a href="#r69" class="usa-link" aria-describedby="r69">69</a>,<a href="#r102" class="usa-link" aria-describedby="r102">102</a>-<a href="#r104" class="usa-link" aria-describedby="r104">104</a>). In our previous study, <em>HER</em>-<em>2</em> mutation was detected in 4.8% (22/456) of <em>EGFR</em> wild-type lung adenocarcinoma (<a href="#r105" class="usa-link" aria-describedby="r105">105</a>). Recently, <em>HER2</em> inhibition therapy with small molecular TKIs, such as afatinib, dacomitinib, neratinib, and lapatinib, may represent a promising therapeutic option in patients with <em>HER2</em> mutations (<a href="#r106" class="usa-link" aria-describedby="r106">106</a>-<a href="#r110" class="usa-link" aria-describedby="r110">110</a>). Pyrotinib (SHR1258, discovered by Shanghai Hengrui Pharmaceutical CO., Ltd.) was a novel irreversible <em>EGFR/HER2</em> dual TKI and demonstrated robust anti-tumor activity in <em>HER2</em>-positive breast cancer both <em>in vivo</em> and <em>in vitro</em> (<a href="#r111" class="usa-link" aria-describedby="r111">111</a>). In a phase I study of pyrotinib in <em>HER2</em>-positive metastatic breast cancer, the maximum tolerated dose was established as 400 mg (<a href="#r112" class="usa-link" aria-describedby="r112">112</a>). Of 36 evaluable patients, the ORR was 50% and median PFS was 35.4 weeks. Furthermore, the ORR was impressive and 10 out of 12 (83.3%) patients achieved an objective response in trastuzumab-pretreated patients. Ren <em>et al.</em> recently reported preliminary results of a phase II study about the efficacy and safety of pyrotinib in Chinese patients with <em>HER2</em>-mutant advanced NSCLC (<a href="#r113" class="usa-link" aria-describedby="r113">113</a>). By Jul 21, 2016, 11 patients were treated with pyrotinib at a dose of 320 or 400 mg orally per day. The ORR was 54.5% (6/11) and disease control rate (DCR) was 81.1% (8/11). The median PFS was 6.2 months and side effects were mild. This trial is still ongoing (<a href="https://clinicaltrials.gov/ct2/show/NCT02535507" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02535507</a>) and we expectantly await further results.</p></section></section><section id="sec10"><h2 class="pmc_sec_title">Lung SQCC or SCLC in never-smoking East Asian: potentially distinct subtypes?</h2>
<p>Lung SQCC and SCLC are two common histologic type of smoking-related lung cancer. The incidence of never-smoking lung cancer increased over time both in Asian patients and non-Asian patients, although the reason remains unknown. Furthermore, the proportion of never-smokers is higher among Asian patients with lung cancer than in non-Asian patients, therefore, a better understanding of the epidemiologic and biologic characteristics of never-smokers has become increasingly important, especially in Asian patients.</p>
<p>Huang <em>et al.</em> recently characterized the clinical features and specific driver genes status of never-smoking lung SQCC in 597 Chinese patients (<a href="#r114" class="usa-link" aria-describedby="r114">114</a>). Overall, 14.7% (88/597) were never-smokers. The never-smokers were more likely to be female patients than ever-smokers (42.05% <em>vs.</em> 1.57%, P&lt;0.001). Among the 76 never-smokers who had high quality tissue to detect oncogenic mutations, 16 harbored known oncogenic mutations, including 10 (13.16%) <em>EGFR</em> mutations, 1 (1.32%) <em>Kras</em> mutations, 2 (2.63%) <em>HER2</em> mutations, 1 (1.32%) <em>BRAF</em> mutations, 2 (2.63%) <em>PIK3CA</em> mutations and 2 (2.63%) <em>FGFR</em> fusion. The prevalence of oncogenic drivers was significantly higher in never-smokers than that in ever-smokers (21.05% <em>vs.</em> 11.05%, P=0.023), especially <em>EGFR</em> mutations (13.16% <em>vs.</em> 3.40%, P=0.001). Furthermore, never-smokers tended to have poorer OS than ever-smokers. In another study of South Korean patients, 5.0% (19/379) were never-smokers (<a href="#r115" class="usa-link" aria-describedby="r115">115</a>). Similarly, of these 19 patients, 52.5% (10/19) were females. The investigators further analyzed fifty cancer-related genes in never-smokers (12 patients) and ever-smokers (14 patients). Although the distribution of hotspot mutations in never-smokers was similar to that in ever-smokers, <em>EGFR</em> mutations were found in both never-smokers and ever-smokers. Generally, in SQCC patients with <em>EGFR</em> sensitizing mutations, EGFR-TKIs are generally less effective than in adenocarcinoma (<a href="#r116" class="usa-link" aria-describedby="r116">116</a>). Of note, in that study, among 4 never-smokers with lung SQCC with evaluable data, 1 achieved complete response, 1 achieved partial response, and 2 achieved stable disease (<a href="#r116" class="usa-link" aria-describedby="r116">116</a>). In another study conducted in China, among 51 non-adenocarcinoma patients with <em>EGFR</em> sensitizing mutations treated with EGFR-TKIs (26 with SQCC), the median PFS was longer in never-smokers than ever-smokers (5.49 <em>vs.</em> 3.78 months, P=0.036) (<a href="#r117" class="usa-link" aria-describedby="r117">117</a>). Several cases also observed a significantly clinical benefit from crizotinib or alectinib in patients with <em>ALK</em>/<em>ROS1</em>-rearranged SQCC (<a href="#r118" class="usa-link" aria-describedby="r118">118</a>-<a href="#r122" class="usa-link" aria-describedby="r122">122</a>) (<a href="#t1" class="usa-link"><em>Table 1</em></a>). Interestingly, all these patients mentioned above were never-smokers and one patient who did not respond to alectinib was an ever-smoker SQCC (<a href="#r123" class="usa-link" aria-describedby="r123">123</a>) (<a href="#t1" class="usa-link"><em>Table 1</em></a>). These results, at least in part, suggest that lung SQCCs in never-smokers may be a distinct subtype, and further research into lung SQCC in never-smokers is needed.</p>
<section class="tw xbox font-sm" id="t1"><h3 class="obj_head">Table 1. Cases of East Asian patients with squamous cell carcinoma harboring <em>ALK/ROS1</em> fusions.</h3>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col width="9.71%" span="1">
<col width="5.38%" span="1">
<col width="9.64%" span="1">
<col width="6.48%" span="1">
<col width="6.2%" span="1">
<col width="6.62%" span="1">
<col width="7.86%" span="1">
<col width="5.24%" span="1">
<col width="11.3%" span="1">
<col width="6.89%" span="1">
<col width="9.93%" span="1">
<col width="7.99%" span="1">
<col width="6.76%" span="1">
<thead><tr>
<th valign="middle" align="left" scope="col" rowspan="1" colspan="1">Author</th>
<th valign="middle" align="center" scope="col" rowspan="1" colspan="1">Year</th>
<th valign="middle" align="center" scope="col" rowspan="1" colspan="1">Race</th>
<th valign="middle" align="center" scope="col" rowspan="1" colspan="1">Gender</th>
<th valign="middle" align="center" scope="col" rowspan="1" colspan="1">Age (years)</th>
<th valign="middle" align="center" scope="col" rowspan="1" colspan="1">Pathology</th>
<th valign="middle" align="center" scope="col" rowspan="1" colspan="1">Smoking status</th>
<th valign="middle" align="center" scope="col" rowspan="1" colspan="1">Stage</th>
<th valign="middle" align="center" scope="col" rowspan="1" colspan="1">Molecular alteration</th>
<th valign="middle" align="center" scope="col" rowspan="1" colspan="1">treatment</th>
<th valign="middle" align="center" scope="col" rowspan="1" colspan="1">Best response</th>
<th valign="middle" align="center" scope="col" rowspan="1" colspan="1">PFS (months)</th>
<th valign="middle" align="center" scope="col" rowspan="1" colspan="1">Reference</th>
</tr></thead>
<tbody>
<tr>
<td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Wang <em>et al.</em>
</td>
<td valign="middle" align="center" rowspan="1" colspan="1">2014</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Chinese</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Female</td>
<td valign="middle" align="center" rowspan="1" colspan="1">55</td>
<td valign="middle" align="center" rowspan="1" colspan="1">SQCC</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Never</td>
<td valign="middle" align="center" rowspan="1" colspan="1">IV</td>
<td valign="middle" align="center" rowspan="1" colspan="1">ALK fusion</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Crizotinib</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Partial response</td>
<td valign="middle" align="center" rowspan="1" colspan="1">5.8+</td>
<td valign="middle" align="center" rowspan="1" colspan="1">(<a href="#r118" class="usa-link" aria-describedby="r118">118</a>)</td>
</tr>
<tr>
<td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Zhang <em>et al.</em>
</td>
<td valign="middle" align="center" rowspan="1" colspan="1">2015</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Chinese</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Female</td>
<td valign="middle" align="center" rowspan="1" colspan="1">55</td>
<td valign="middle" align="center" rowspan="1" colspan="1">SQCC</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Never</td>
<td valign="middle" align="center" rowspan="1" colspan="1">IV</td>
<td valign="middle" align="center" rowspan="1" colspan="1">ALK fusion</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Crizotinib</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Partial response</td>
<td valign="middle" align="center" rowspan="1" colspan="1">6</td>
<td valign="middle" align="center" rowspan="1" colspan="1">(<a href="#r119" class="usa-link" aria-describedby="r119">119</a>)</td>
</tr>
<tr>
<td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Wang <em>et al.</em>
</td>
<td valign="middle" align="center" rowspan="1" colspan="1">2016</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Chinese</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Female</td>
<td valign="middle" align="center" rowspan="1" colspan="1">37</td>
<td valign="middle" align="center" rowspan="1" colspan="1">SQCC</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Never</td>
<td valign="middle" align="center" rowspan="1" colspan="1">IIIB</td>
<td valign="middle" align="center" rowspan="1" colspan="1">ALK fusion</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Crizotinib</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Partial response</td>
<td valign="middle" align="center" rowspan="1" colspan="1">9+</td>
<td valign="middle" align="center" rowspan="1" colspan="1">(<a href="#r120" class="usa-link" aria-describedby="r120">120</a>)</td>
</tr>
<tr>
<td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Mamesaya <em>et al.</em>
</td>
<td valign="middle" align="center" rowspan="1" colspan="1">2017</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Japanese-Brazilian</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Female</td>
<td valign="middle" align="center" rowspan="1" colspan="1">52</td>
<td valign="middle" align="center" rowspan="1" colspan="1">SQCC</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Never</td>
<td valign="middle" align="center" rowspan="1" colspan="1">IV</td>
<td valign="middle" align="center" rowspan="1" colspan="1">ALK fusion</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Alectinib</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Partial response</td>
<td valign="middle" align="center" rowspan="1" colspan="1">11+</td>
<td valign="middle" align="center" rowspan="1" colspan="1">(<a href="#r121" class="usa-link" aria-describedby="r121">121</a>)</td>
</tr>
<tr>
<td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Li <em>et al.</em>
</td>
<td valign="middle" align="center" rowspan="1" colspan="1">2017</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Chinese</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Female</td>
<td valign="middle" align="center" rowspan="1" colspan="1">47</td>
<td valign="middle" align="center" rowspan="1" colspan="1">SQCC</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Never</td>
<td valign="middle" align="center" rowspan="1" colspan="1">IV</td>
<td valign="middle" align="center" rowspan="1" colspan="1">ALK-ROS1 fusion</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Crizotinib</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Partial response</td>
<td valign="middle" align="center" rowspan="1" colspan="1">5</td>
<td valign="middle" align="center" rowspan="1" colspan="1">(<a href="#r122" class="usa-link" aria-describedby="r122">122</a>)</td>
</tr>
<tr>
<td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Tamiya <em>et al.</em>
</td>
<td valign="middle" align="center" rowspan="1" colspan="1">2015</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Japanese</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Male</td>
<td valign="middle" align="center" rowspan="1" colspan="1">78</td>
<td valign="middle" align="center" rowspan="1" colspan="1">SQCC</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Ever</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Unknown</td>
<td valign="middle" align="center" rowspan="1" colspan="1">ALK fusion</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Alectinib</td>
<td valign="middle" align="center" rowspan="1" colspan="1">Stable disease</td>
<td valign="middle" align="center" rowspan="1" colspan="1">1.5+</td>
<td valign="middle" align="center" rowspan="1" colspan="1">(<a href="#r123" class="usa-link" aria-describedby="r123">123</a>)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/t1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p24"><p>PFS, progression-free survival; SQCC, squamous cell carcinoma.</p></div></div></section><p>The prevalence of never-smokers with SCLC in Caucasian patients is very low, accounting for 2.0% to 2.5% of all SCLC cases (<a href="#r124" class="usa-link" aria-describedby="r124">124</a>,<a href="#r125" class="usa-link" aria-describedby="r125">125</a>). Two recent studies showed that the proportion of never-smokers with SCLC in East Asian patients was higher than that in Caucasian patients (<a href="#r12" class="usa-link" aria-describedby="r12">12</a>,<a href="#r13" class="usa-link" aria-describedby="r13">13</a>). In the study by Sun <em>et al.</em>, 13% (50/391) were never-smokers in South Korean patients. In our study, 22.8% (69/303) were never-smokers in Chinese patients (<a href="#r12" class="usa-link" aria-describedby="r12">12</a>). Furthermore, more than 80% of never-smokers were females. Both studies demonstrated that never-smokers with SCLC had better survival than ever-smokers (<a href="#r12" class="usa-link" aria-describedby="r12">12</a>,<a href="#r13" class="usa-link" aria-describedby="r13">13</a>). Of 28 genetically evaluable never-smokers, <em>EGFR</em> mutations were detected in four cases (14.3%), and other molecular alterations included <em>TP53</em> in 26 cases (92.9%), <em>RB1</em> in 7 cases (25%), <em>PTEN</em> in 5 cases (17.9%), <em>MET</em> in 4 cases (14.3%), and <em>SMAD4</em> in 3 cases (10/7%) in the study by Sun <em>et al.</em> (<a href="#r13" class="usa-link" aria-describedby="r13">13</a>). Although <em>EGFR</em> mutations can be found in SCLC phenotypically transformed from adenocarcinoma as an acquired resistance mechanism to EGFR-TKIs, these 4 cases were found in patients with <em>de novo</em> SCLC. A recent case revealed that one never-smoking patient with <em>de novo</em> SCLC harboring <em>EGFR</em> exon 19 deletion but had no response to erlotinib (<a href="#r126" class="usa-link" aria-describedby="r126">126</a>). However, due to the high proportion of never-smokers among Asian SCLC patients, better understanding of the biologic characteristics of these subtypes of patients may provide new insights for the treatment strategies that have not changed for decades.</p></section><section id="sec11"><h2 class="pmc_sec_title">Immunotherapy in never-smoking East Asian: can a patient population not always be blessed?</h2>
<p>Immunotherapy with immune checkpoint blockade targeting the programmed-death 1/programmed-death ligand 1 (PD-1/PD-L1) axis represents a novel approach for the treatment of patients with advanced NSCLC (<a href="#r127" class="usa-link" aria-describedby="r127">127</a>). Several randomized trials have demonstrated a significant survival advantages of PD-1/PD-L1 antibodies over docetaxel as second-line therapy (<a href="#r128" class="usa-link" aria-describedby="r128">128</a>-<a href="#r132" class="usa-link" aria-describedby="r132">132</a>). Furthermore, pembrolizumab has been approved as first-line therapy for advanced NSCLC patients with PD-L1 positive tumors (≥50%) based on the results of KEYNOTE-024 trial (<a href="#r133" class="usa-link" aria-describedby="r133">133</a>). Of note, the current obstacle to the wide use of anti-PD-1/PD-L1 antibodies is lack of biomarker to identify beneficial patient population because only about 20% of patients with NSCLC respond to anti-PD-1/PD-L1 antibodies. Tumor mutation burden (TMB) has recently been identified as a promising biomarker for response to immune checkpoint inhibitors (<a href="#r134" class="usa-link" aria-describedby="r134">134</a>). Patients with high nonsynonymous burden had higher ORR (63% <em>vs.</em> 0%, P=0.03) and better PFS (14.5 <em>vs.</em> 3.7 months, HR =0.19, 95% CI: 0.05–0.70, P=0.01) than those with low nonsynonymous burden. High TMB can increase the number of neoantigens, which are recognized by T cells, therefore enhancing tumor immunogenicity and leading to an antitumor immune response (<a href="#r134" class="usa-link" aria-describedby="r134">134</a>). These preliminary findings have been confirmed in an exploratory analysis of CheckMate-026 trial (<a href="#r135" class="usa-link" aria-describedby="r135">135</a>). In CheckMate-026 trial, although nivolumab did not prolong the PFS as compared with chemotherapy in patients with previously untreated advanced NSCLC with PD-L1-positive tumors (≥5%), the ORR (47% <em>vs.</em> 28%) and PFS (9.7 <em>vs.</em> 5.8 months, HR =0.62, 95% CI: 0.38–1.00) were significantly improved with the use of nivolumab in patients with high TMB (<a href="#r135" class="usa-link" aria-describedby="r135">135</a>). Genomic analysis has demonstrated that smokers had a significantly higher number of mutations per Mb (median 10.5, range 4.9–17.6) than never-smokers with NSCLC (median 0.6, range 0.6–0.9) (<a href="#r134" class="usa-link" aria-describedby="r134">134</a>). Therefore, smokers are more likely to induce greater TMB and derive clinical benefit from checkpoint inhibitors than never-smokers. Interestingly, Kinoshita <em>et al.</em> found that non-smokers with adenocarcinoma can generate an immunosuppressive tumor microenvironment and inhibit CD8<sup>+</sup> T-cell activation, suggesting checkpoint inhibitors may not be effective in this subtype of patients (<a href="#r136" class="usa-link" aria-describedby="r136">136</a>). However, in a recent meta-analysis, the treatment benefit for checkpoint inhibitors was independent of smoking history (current and former smokers <em>vs.</em> never smokers: HR for death, 0.69 <em>vs.</em> 0.79; interaction, P=0.40) (<a href="#r137" class="usa-link" aria-describedby="r137">137</a>). Actually, it is the molecular smoking signature rather than self-reported smoking history that is significantly related to the clinical benefit from checkpoint inhibitors (<a href="#r134" class="usa-link" aria-describedby="r134">134</a>). Therefore, there is currently lack of robust evidence to select the beneficial population by smoking history for checkpoint inhibitor therapy.</p>
<p>As mentioned above, the vast majority of never-smoking East Asians with NSCLC have adenocarcinoma, a subtype largely defined by oncogenic drivers. Although tremendous efficacy has been achieved in these patients with the administration of targeted therapy, the survival outcomes are not satisfactory. Whether checkpoint inhibitors can generate a durable response of these patients, therefore, becomes of great importance. However, recent randomized trials and meta-analysis revealed that patients with <em>EGFR</em> mutations did not derive survival benefit from checkpoint inhibitors (<a href="#r128" class="usa-link" aria-describedby="r128">128</a>-<a href="#r132" class="usa-link" aria-describedby="r132">132</a>,<a href="#r138" class="usa-link" aria-describedby="r138">138</a>). A recent retrospective study also demonstrated that <em>EGFR</em> mutations or <em>ALK</em> rearrangement was associated with low response to checkpoint inhibitors (3.6%, 1/28) (<a href="#r139" class="usa-link" aria-describedby="r139">139</a>). The poor response to checkpoint inhibitors in patients with <em>EGFR</em> mutations or <em>ALK</em> rearrangement may result from a potentially immunosuppressive microenvironment in these patients (<a href="#r139" class="usa-link" aria-describedby="r139">139</a>). <em>EGFR</em> mutation was also correlated with uninflamed phenotype and weak immunogenicity, with decreased PD-L1 expression, lack of T-cell infiltration, and lower TMB (<a href="#r140" class="usa-link" aria-describedby="r140">140</a>). A recent report showed that High CD73 expression in <em>EGFR</em>-mutant NSCLC may be another cause that contribute to the reduced benefit from checkpoint inhibitors, which can alter immune cell function and is correlated with low PD-L1 expression (<a href="#r141" class="usa-link" aria-describedby="r141">141</a>). Sabari et al recently reported preliminary results of immunotherapy in NSCLC with METex14 skipping (<a href="#r142" class="usa-link" aria-describedby="r142">142</a>). However, only 1 patient (6.7%, 1/15) responded to checkpoint inhibitors and median PFS was only 2.3 months. TMB was lower in patients with METex14 skipping and no partial response was observed even in patients with high TMB (<a href="#r142" class="usa-link" aria-describedby="r142">142</a>). Current evidence suggests that never-smoking adenocarcinoma from East Asia, the potentially beneficial population of targeted therapy, do not seem to be the same beneficial population of immunotherapy.</p>
<p>Notably, although this review focuses on East Asia, most of the data comes from China, Japan, and South Korea and we have little information about Mongolia and North Korea. Furthermore, China is a huge country with a diverse ethnic population. Almost all the reported data in Chinese targets Han population. As the ethnic minorities have distinct life-styles, growing backgrounds, diets and living conditions compared with Han population, the genetic profiles may also differ. For example, Uyghur population, mainly living in North-west of China, had significantly lower <em>EGFR</em> mutation rate than Han population (12% <em>vs.</em> 55.1%) (<a href="#r143" class="usa-link" aria-describedby="r143">143</a>). Therefore, these experiences and treatment strategies cannot be directly generalized to other East Asians, namely Mongolians and North Koreans, and Chinese ethnic minorities, and further studies are still needed in these populations.</p></section><section id="sec12"><h2 class="pmc_sec_title">Conclusions</h2>
<p>In summary, approximately one third of all lung cancer patients in East Asia are LCINS. Never-smokers are more often diagnosed with adenocarcinoma in East Asian, a subtype largely defined by oncogenic drivers. In this subgroup of patients, as high as 90% of patients have been found to harbor well-known oncogenic mutations and can be successfully managed with targeted therapy inhibiting specific oncogenic mutant kinases. Lung SQCC and SCLC are two common histologic type of smoking-related NSCLC. The incidence of LCINS also increases over time in East Asian patients. Recent studies suggest that lung SQCC and SCLC in never-smokers may be distinct subtypes, and better understanding of the biologic characteristics of these subtypes of patients may provide new insights for the treatment of these patients. Although Immunotherapy with immune checkpoint blockade generates durable response in some patients with advanced NSCLC, lung adenocarcinoma from East Asian never-smokers do not seem to be the beneficial population. These findings may reflect the considerably lower total mutation burden (and thus fewer neoantigens) in never smokers. However, there is currently lack of robust evidence to guide checkpoint inhibitor treatment by smoking history.</p></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>None.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn2"><p><em>Conflicts of Interest</em>: The authors have no conflicts of interest to declare.</p></div></div></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="r1">
<span class="label">1.</span><cite>Chen W, Zheng R, Baade PD, et al. 
Cancer statistics in China, 2015.
CA Cancer J Clin
2016;66:115-32. 10.3322/caac.21338</cite> [<a href="https://doi.org/10.3322/caac.21338" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26808342/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=CA%20Cancer%20J%20Clin&amp;title=Cancer%20statistics%20in%20China,%202015.&amp;author=W%20Chen&amp;author=R%20Zheng&amp;author=PD%20Baade&amp;volume=66&amp;publication_year=2016&amp;pages=115-32&amp;pmid=26808342&amp;doi=10.3322/caac.21338&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r2">
<span class="label">2.</span><cite>Ferlay J, Shin HR. =Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
Int J Cancer
2010;127:2893-917. 10.1002/ijc.25516</cite> [<a href="https://doi.org/10.1002/ijc.25516" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21351269/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Cancer&amp;title=Estimates%20of%20worldwide%20burden%20of%20cancer%20in%202008:%20GLOBOCAN%202008.&amp;author=J%20Ferlay&amp;author=HR%20Shin&amp;volume=127&amp;publication_year=2010&amp;pages=2893-917&amp;pmid=21351269&amp;doi=10.1002/ijc.25516&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r3">
<span class="label">3.</span><cite>Parkin DM, Bray F, Ferlay J, et al. 
Global cancer statistics, 2002.
CA Cancer J Clin
2005;55:74-108. 10.3322/canjclin.55.2.74</cite> [<a href="https://doi.org/10.3322/canjclin.55.2.74" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15761078/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=CA%20Cancer%20J%20Clin&amp;title=Global%20cancer%20statistics,%202002.&amp;author=DM%20Parkin&amp;author=F%20Bray&amp;author=J%20Ferlay&amp;volume=55&amp;publication_year=2005&amp;pages=74-108&amp;pmid=15761078&amp;doi=10.3322/canjclin.55.2.74&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r4">
<span class="label">4.</span><cite>Cho J, Choi SM, Lee J, et al. 
Proportion and clinical features of never-smokers with non-small cell lung cancer.
Chin J Cancer
2017;36:20. 10.1186/s40880-017-0187-6</cite> [<a href="https://doi.org/10.1186/s40880-017-0187-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5299770/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28179026/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Chin%20J%20Cancer&amp;title=Proportion%20and%20clinical%20features%20of%20never-smokers%20with%20non-small%20cell%20lung%20cancer.&amp;author=J%20Cho&amp;author=SM%20Choi&amp;author=J%20Lee&amp;volume=36&amp;publication_year=2017&amp;pages=20&amp;pmid=28179026&amp;doi=10.1186/s40880-017-0187-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r5">
<span class="label">5.</span><cite>Yano T, Miura N, Takenaka T, et al. 
Never-smoking nonsmall cell lung cancer as a separate entity: clinicopathologic features and survival.
Cancer
2008;113:1012-8. 10.1002/cncr.23679</cite> [<a href="https://doi.org/10.1002/cncr.23679" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18618510/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Never-smoking%20nonsmall%20cell%20lung%20cancer%20as%20a%20separate%20entity:%20clinicopathologic%20features%20and%20survival.&amp;author=T%20Yano&amp;author=N%20Miura&amp;author=T%20Takenaka&amp;volume=113&amp;publication_year=2008&amp;pages=1012-8&amp;pmid=18618510&amp;doi=10.1002/cncr.23679&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r6">
<span class="label">6.</span><cite>Kosaka T, Yatabe Y, Endoh H, et al. 
Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.
Cancer Res
2004;64:8919-23. 10.1158/0008-5472.CAN-04-2818</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-04-2818" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15604253/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=Mutations%20of%20the%20epidermal%20growth%20factor%20receptor%20gene%20in%20lung%20cancer:%20biological%20and%20clinical%20implications.&amp;author=T%20Kosaka&amp;author=Y%20Yatabe&amp;author=H%20Endoh&amp;volume=64&amp;publication_year=2004&amp;pages=8919-23&amp;pmid=15604253&amp;doi=10.1158/0008-5472.CAN-04-2818&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r7">
<span class="label">7.</span><cite>Tam IY, Chung LP, Suen WS, et al. 
Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.
Clin Cancer Res
2006;12:1647-53. 10.1158/1078-0432.CCR-05-1981</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-05-1981" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16533793/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Distinct%20epidermal%20growth%20factor%20receptor%20and%20KRAS%20mutation%20patterns%20in%20non-small%20cell%20lung%20cancer%20patients%20with%20different%20tobacco%20exposure%20and%20clinicopathologic%20features.&amp;author=IY%20Tam&amp;author=LP%20Chung&amp;author=WS%20Suen&amp;volume=12&amp;publication_year=2006&amp;pages=1647-53&amp;pmid=16533793&amp;doi=10.1158/1078-0432.CCR-05-1981&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r8">
<span class="label">8.</span><cite>Hsu LH, Chu NM, Liu CC, et al. 
Sex-associated differences in non-small cell lung cancer in the new era: is gender an independent prognostic factor?
Lung Cancer
2009;66:262-7. 10.1016/j.lungcan.2009.01.020</cite> [<a href="https://doi.org/10.1016/j.lungcan.2009.01.020" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19299032/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung%20Cancer&amp;title=Sex-associated%20differences%20in%20non-small%20cell%20lung%20cancer%20in%20the%20new%20era:%20is%20gender%20an%20independent%20prognostic%20factor?&amp;author=LH%20Hsu&amp;author=NM%20Chu&amp;author=CC%20Liu&amp;volume=66&amp;publication_year=2009&amp;pages=262-7&amp;pmid=19299032&amp;doi=10.1016/j.lungcan.2009.01.020&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r9">
<span class="label">9.</span><cite>Mitsudomi T.
Molecular epidemiology of lung cancer and geographic variations with special reference to EGFR mutations.
Transl Lung Cancer Res
2014;3:205-11.</cite> [<a href="https://doi.org/10.3978/j.issn.2218-6751.2014.08.04" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4367697/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25806302/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Transl%20Lung%20Cancer%20Res&amp;title=Molecular%20epidemiology%20of%20lung%20cancer%20and%20geographic%20variations%20with%20special%20reference%20to%20EGFR%20mutations.&amp;author=T.%20Mitsudomi&amp;volume=3&amp;publication_year=2014&amp;pages=205-11&amp;pmid=25806302&amp;doi=10.3978/j.issn.2218-6751.2014.08.04&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r10">
<span class="label">10.</span><cite>Kobrinsky NL, Klug MG, Hokanson PJ, et al. 
Impact of smoking on cancer stage at diagnosis.
J Clin Oncol
2003;21:907-13. 10.1200/JCO.2003.05.110</cite> [<a href="https://doi.org/10.1200/JCO.2003.05.110" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12610192/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Impact%20of%20smoking%20on%20cancer%20stage%20at%20diagnosis.&amp;author=NL%20Kobrinsky&amp;author=MG%20Klug&amp;author=PJ%20Hokanson&amp;volume=21&amp;publication_year=2003&amp;pages=907-13&amp;pmid=12610192&amp;doi=10.1200/JCO.2003.05.110&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r11">
<span class="label">11.</span><cite>Sun Y, Ren Y, Fang Z, et al. 
Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.
J Clin Oncol
2010;28:4616-20. 10.1200/JCO.2010.29.6038</cite> [<a href="https://doi.org/10.1200/JCO.2010.29.6038" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2974342/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20855837/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Lung%20adenocarcinoma%20from%20East%20Asian%20never-smokers%20is%20a%20disease%20largely%20defined%20by%20targetable%20oncogenic%20mutant%20kinases.&amp;author=Y%20Sun&amp;author=Y%20Ren&amp;author=Z%20Fang&amp;volume=28&amp;publication_year=2010&amp;pages=4616-20&amp;pmid=20855837&amp;doi=10.1200/JCO.2010.29.6038&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r12">
<span class="label">12.</span><cite>Liu X, Jiang T, Li W, et al. 
Characterization of never-smoking and its association with clinical outcomes in Chinese patients with small-cell lung cancer.
Lung Cancer
2018;115:109-15. 10.1016/j.lungcan.2017.11.022</cite> [<a href="https://doi.org/10.1016/j.lungcan.2017.11.022" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29290250/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung%20Cancer&amp;title=Characterization%20of%20never-smoking%20and%20its%20association%20with%20clinical%20outcomes%20in%20Chinese%20patients%20with%20small-cell%20lung%20cancer.&amp;author=X%20Liu&amp;author=T%20Jiang&amp;author=W%20Li&amp;volume=115&amp;publication_year=2018&amp;pages=109-15&amp;pmid=29290250&amp;doi=10.1016/j.lungcan.2017.11.022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r13">
<span class="label">13.</span><cite>Sun JM, Choi YL, Ji JH, et al. 
Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing.
Ann Oncol
2015;26:161-6. 10.1093/annonc/mdu504</cite> [<a href="https://doi.org/10.1093/annonc/mdu504" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25355724/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol&amp;title=Small-cell%20lung%20cancer%20detection%20in%20never-smokers:%20clinical%20characteristics%20and%20multigene%20mutation%20profiling%20using%20targeted%20next-generation%20sequencing.&amp;author=JM%20Sun&amp;author=YL%20Choi&amp;author=JH%20Ji&amp;volume=26&amp;publication_year=2015&amp;pages=161-6&amp;pmid=25355724&amp;doi=10.1093/annonc/mdu504&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r14">
<span class="label">14.</span><cite>Kim CH, Lee YC, Hung RJ, et al. 
Exposure to secondhand tobacco smoke and lung cancer by histological type: a pooled analysis of the International Lung Cancer Consortium (ILCCO).
Int J Cancer
2014;135:1918-30. 10.1002/ijc.28835</cite> [<a href="https://doi.org/10.1002/ijc.28835" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4126868/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24615328/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Cancer&amp;title=Exposure%20to%20secondhand%20tobacco%20smoke%20and%20lung%20cancer%20by%20histological%20type:%20a%20pooled%20analysis%20of%20the%20International%20Lung%20Cancer%20Consortium%20(ILCCO).&amp;author=CH%20Kim&amp;author=YC%20Lee&amp;author=RJ%20Hung&amp;volume=135&amp;publication_year=2014&amp;pages=1918-30&amp;pmid=24615328&amp;doi=10.1002/ijc.28835&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r15">
<span class="label">15.</span><cite>Li Q, Hsia J, Yang G.
Prevalence of smoking in China in 2010.
N Engl J Med
2011;364:2469-70. 10.1056/NEJMc1102459</cite> [<a href="https://doi.org/10.1056/NEJMc1102459" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21696322/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Prevalence%20of%20smoking%20in%20China%20in%202010.&amp;author=Q%20Li&amp;author=J%20Hsia&amp;author=G%20Yang&amp;volume=364&amp;publication_year=2011&amp;pages=2469-70&amp;pmid=21696322&amp;doi=10.1056/NEJMc1102459&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r16">
<span class="label">16.</span><cite>Giovino GA, Mirza SA, Samet JM, et al. 
Tobacco use in 3 billion individuals from 16 countries: an analysis of nationally representative cross-sectional household surveys.
Lancet
2012;380:668-79. 10.1016/S0140-6736(12)61085-X</cite> [<a href="https://doi.org/10.1016/S0140-6736(12)61085-X" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22901888/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Tobacco%20use%20in%203%20billion%20individuals%20from%2016%20countries:%20an%20analysis%20of%20nationally%20representative%20cross-sectional%20household%20surveys.&amp;author=GA%20Giovino&amp;author=SA%20Mirza&amp;author=JM%20Samet&amp;volume=380&amp;publication_year=2012&amp;pages=668-79&amp;pmid=22901888&amp;doi=10.1016/S0140-6736(12)61085-X&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r17">
<span class="label">17.</span><cite>Yu IT, Chiu YL, Au JS, et al. 
Dose-response relationship between cooking fumes exposures and lung cancer among Chinese nonsmoking women.
Cancer Res
2006;66:4961-7. 10.1158/0008-5472.CAN-05-2932</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-05-2932" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16651454/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=Dose-response%20relationship%20between%20cooking%20fumes%20exposures%20and%20lung%20cancer%20among%20Chinese%20nonsmoking%20women.&amp;author=IT%20Yu&amp;author=YL%20Chiu&amp;author=JS%20Au&amp;volume=66&amp;publication_year=2006&amp;pages=4961-7&amp;pmid=16651454&amp;doi=10.1158/0008-5472.CAN-05-2932&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r18">
<span class="label">18.</span><cite>Ko YC, Lee CH, Chen MJ, et al. 
Risk factors for primary lung cancer among non-smoking women in Taiwan.
Int J Epidemiol
1997;26:24-31. 10.1093/ije/26.1.24</cite> [<a href="https://doi.org/10.1093/ije/26.1.24" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9126500/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Epidemiol&amp;title=Risk%20factors%20for%20primary%20lung%20cancer%20among%20non-smoking%20women%20in%20Taiwan.&amp;author=YC%20Ko&amp;author=CH%20Lee&amp;author=MJ%20Chen&amp;volume=26&amp;publication_year=1997&amp;pages=24-31&amp;pmid=9126500&amp;doi=10.1093/ije/26.1.24&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r19">
<span class="label">19.</span><cite>Ko YC, Cheng LS, Lee CH, et al. 
Chinese food cooking and lung cancer in women nonsmokers.
Am J Epidemiol
2000;151:140-7. 10.1093/oxfordjournals.aje.a010181</cite> [<a href="https://doi.org/10.1093/oxfordjournals.aje.a010181" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10645816/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Epidemiol&amp;title=Chinese%20food%20cooking%20and%20lung%20cancer%20in%20women%20nonsmokers.&amp;author=YC%20Ko&amp;author=LS%20Cheng&amp;author=CH%20Lee&amp;volume=151&amp;publication_year=2000&amp;pages=140-7&amp;pmid=10645816&amp;doi=10.1093/oxfordjournals.aje.a010181&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r20">
<span class="label">20.</span><cite>Wang TJ, Zhou BS, Shi JP.
Lung cancer in nonsmoking Chinese women: a case-control study.
Lung Cancer
1996;14
Suppl 1:S93-8. 10.1016/S0169-5002(96)90214-7</cite> [<a href="https://doi.org/10.1016/S0169-5002(96)90214-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8785672/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung%20Cancer&amp;title=Lung%20cancer%20in%20nonsmoking%20Chinese%20women:%20a%20case-control%20study.&amp;author=TJ%20Wang&amp;author=BS%20Zhou&amp;author=JP%20Shi&amp;volume=14&amp;issue=Suppl%201&amp;publication_year=1996&amp;pages=S93-8&amp;pmid=8785672&amp;doi=10.1016/S0169-5002(96)90214-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r21">
<span class="label">21.</span><cite>Xue Y, Jiang Y, Jin S, et al. 
Association between cooking oil fume exposure and lung cancer among Chinese nonsmoking women: a meta-analysis.
Onco Targets Ther
2016;9:2987-92. 10.2147/OTT.S100949</cite> [<a href="https://doi.org/10.2147/OTT.S100949" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4881732/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27284248/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Onco%20Targets%20Ther&amp;title=Association%20between%20cooking%20oil%20fume%20exposure%20and%20lung%20cancer%20among%20Chinese%20nonsmoking%20women:%20a%20meta-analysis.&amp;author=Y%20Xue&amp;author=Y%20Jiang&amp;author=S%20Jin&amp;volume=9&amp;publication_year=2016&amp;pages=2987-92&amp;pmid=27284248&amp;doi=10.2147/OTT.S100949&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r22">
<span class="label">22.</span><cite>Wu PF, Lee CH, Wang MJ, et al. 
Cancer aggregation and complex segregation analysis of families with female non-smoking lung cancer probands in Taiwan.
Eur J Cancer
2004;40:260-6. 10.1016/j.ejca.2003.08.021</cite> [<a href="https://doi.org/10.1016/j.ejca.2003.08.021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14728941/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Cancer&amp;title=Cancer%20aggregation%20and%20complex%20segregation%20analysis%20of%20families%20with%20female%20non-smoking%20lung%20cancer%20probands%20in%20Taiwan.&amp;author=PF%20Wu&amp;author=CH%20Lee&amp;author=MJ%20Wang&amp;volume=40&amp;publication_year=2004&amp;pages=260-6&amp;pmid=14728941&amp;doi=10.1016/j.ejca.2003.08.021&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r23">
<span class="label">23.</span><cite>Jin Y, Xu Y, Xu M, et al. 
Increased risk of cancer among relatives of patients with lung cancer in China.
BMC Cancer
2005;5:146. 10.1186/1471-2407-5-146</cite> [<a href="https://doi.org/10.1186/1471-2407-5-146" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1299321/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16281985/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Cancer&amp;title=Increased%20risk%20of%20cancer%20among%20relatives%20of%20patients%20with%20lung%20cancer%20in%20China.&amp;author=Y%20Jin&amp;author=Y%20Xu&amp;author=M%20Xu&amp;volume=5&amp;publication_year=2005&amp;pages=146&amp;pmid=16281985&amp;doi=10.1186/1471-2407-5-146&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r24">
<span class="label">24.</span><cite>Jin YT, Xu YC, Yang RD, et al. 
Familial aggregation of lung cancer in a high incidence area in China.
Br J Cancer
2005;92:1321-5. 10.1038/sj.bjc.6602465</cite> [<a href="https://doi.org/10.1038/sj.bjc.6602465" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2361969/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15756270/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Cancer&amp;title=Familial%20aggregation%20of%20lung%20cancer%20in%20a%20high%20incidence%20area%20in%20China.&amp;author=YT%20Jin&amp;author=YC%20Xu&amp;author=RD%20Yang&amp;volume=92&amp;publication_year=2005&amp;pages=1321-5&amp;pmid=15756270&amp;doi=10.1038/sj.bjc.6602465&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r25">
<span class="label">25.</span><cite>Li P, Deng SS, Wang JB, et al. 
Occupational and environmental cancer incidence and mortality in China.
Occup Med (Lond)
2012;62:281-7. 10.1093/occmed/kqs016</cite> [<a href="https://doi.org/10.1093/occmed/kqs016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22411970/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Occup%20Med%20(Lond)&amp;title=Occupational%20and%20environmental%20cancer%20incidence%20and%20mortality%20in%20China.&amp;author=P%20Li&amp;author=SS%20Deng&amp;author=JB%20Wang&amp;volume=62&amp;publication_year=2012&amp;pages=281-7&amp;pmid=22411970&amp;doi=10.1093/occmed/kqs016&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r26">
<span class="label">26.</span><cite>Taioli E, Wynder EL.
Re: Endocrine factors and adenocarcinoma of the lung in women.
J Natl Cancer Inst
1994;86:869-70. 10.1093/jnci/86.11.869</cite> [<a href="https://doi.org/10.1093/jnci/86.11.869" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8182770/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Natl%20Cancer%20Inst&amp;title=Re:%20Endocrine%20factors%20and%20adenocarcinoma%20of%20the%20lung%20in%20women.&amp;author=E%20Taioli&amp;author=EL%20Wynder&amp;volume=86&amp;publication_year=1994&amp;pages=869-70&amp;pmid=8182770&amp;doi=10.1093/jnci/86.11.869&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r27">
<span class="label">27.</span><cite>Brenner AV, Wang Z, Kleinerman RA, et al. 
Previous pulmonary diseases and risk of lung cancer in Gansu Province, China.
Int J Epidemiol
2001;30:118-24. 10.1093/ije/30.1.118</cite> [<a href="https://doi.org/10.1093/ije/30.1.118" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11171871/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Epidemiol&amp;title=Previous%20pulmonary%20diseases%20and%20risk%20of%20lung%20cancer%20in%20Gansu%20Province,%20China.&amp;author=AV%20Brenner&amp;author=Z%20Wang&amp;author=RA%20Kleinerman&amp;volume=30&amp;publication_year=2001&amp;pages=118-24&amp;pmid=11171871&amp;doi=10.1093/ije/30.1.118&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r28">
<span class="label">28.</span><cite>Wang SY, Hu YL, Wu YL, et al. 
A comparative study of the risk factors for lung cancer in Guangdong, China.
Lung Cancer
1996;14
Suppl 1:S99-105. 10.1016/S0169-5002(96)90215-9</cite> [<a href="https://doi.org/10.1016/S0169-5002(96)90215-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8785673/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung%20Cancer&amp;title=A%20comparative%20study%20of%20the%20risk%20factors%20for%20lung%20cancer%20in%20Guangdong,%20China.&amp;author=SY%20Wang&amp;author=YL%20Hu&amp;author=YL%20Wu&amp;volume=14&amp;issue=Suppl%201&amp;publication_year=1996&amp;pages=S99-105&amp;pmid=8785673&amp;doi=10.1016/S0169-5002(96)90215-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r29">
<span class="label">29.</span><cite>Mizushima Y, Kobayashi M.
Clinical characteristics of synchronous multiple lung cancer associated with idiopathic pulmonary fibrosis. A review of Japanese cases.
Chest
1995;108:1272-7. 10.1378/chest.108.5.1272</cite> [<a href="https://doi.org/10.1378/chest.108.5.1272" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/7587428/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Chest&amp;title=Clinical%20characteristics%20of%20synchronous%20multiple%20lung%20cancer%20associated%20with%20idiopathic%20pulmonary%20fibrosis.%20A%20review%20of%20Japanese%20cases.&amp;author=Y%20Mizushima&amp;author=M%20Kobayashi&amp;volume=108&amp;publication_year=1995&amp;pages=1272-7&amp;pmid=7587428&amp;doi=10.1378/chest.108.5.1272&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r30">
<span class="label">30.</span><cite>Engels EA, Shen M, Chapman RS, et al. 
Tuberculosis and subsequent risk of lung cancer in Xuanwei, China.
Int J Cancer
2009;124:1183-7. 10.1002/ijc.24042</cite> [<a href="https://doi.org/10.1002/ijc.24042" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2610239/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19058197/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Cancer&amp;title=Tuberculosis%20and%20subsequent%20risk%20of%20lung%20cancer%20in%20Xuanwei,%20China.&amp;author=EA%20Engels&amp;author=M%20Shen&amp;author=RS%20Chapman&amp;volume=124&amp;publication_year=2009&amp;pages=1183-7&amp;pmid=19058197&amp;doi=10.1002/ijc.24042&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r31">
<span class="label">31.</span><cite>Ren S, Kuang P, Zheng L, et al. 
Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma.
Cell Biochem Biophys
2012;64:155-60. 10.1007/s12013-012-9384-8</cite> [<a href="https://doi.org/10.1007/s12013-012-9384-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22707299/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Biochem%20Biophys&amp;title=Analysis%20of%20driver%20mutations%20in%20female%20non-smoker%20Asian%20patients%20with%20pulmonary%20adenocarcinoma.&amp;author=S%20Ren&amp;author=P%20Kuang&amp;author=L%20Zheng&amp;volume=64&amp;publication_year=2012&amp;pages=155-60&amp;pmid=22707299&amp;doi=10.1007/s12013-012-9384-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r32">
<span class="label">32.</span><cite>Li C, Fang R, Sun Y, et al. 
Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers.
PLoS One
2011;6:e28204. 10.1371/journal.pone.0028204</cite> [<a href="https://doi.org/10.1371/journal.pone.0028204" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3227646/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22140546/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20One&amp;title=Spectrum%20of%20oncogenic%20driver%20mutations%20in%20lung%20adenocarcinomas%20from%20East%20Asian%20never%20smokers.&amp;author=C%20Li&amp;author=R%20Fang&amp;author=Y%20Sun&amp;volume=6&amp;publication_year=2011&amp;pages=e28204&amp;pmid=22140546&amp;doi=10.1371/journal.pone.0028204&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r33">
<span class="label">33.</span><cite>Zhang Y, Sun Y, Pan Y, et al. 
Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.
Clin Cancer Res
2012;18:1947-53. 10.1158/1078-0432.CCR-11-2511</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-11-2511" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3319848/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22317764/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Frequency%20of%20driver%20mutations%20in%20lung%20adenocarcinoma%20from%20female%20never-smokers%20varies%20with%20histologic%20subtypes%20and%20age%20at%20diagnosis.&amp;author=Y%20Zhang&amp;author=Y%20Sun&amp;author=Y%20Pan&amp;volume=18&amp;publication_year=2012&amp;pages=1947-53&amp;pmid=22317764&amp;doi=10.1158/1078-0432.CCR-11-2511&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r34">
<span class="label">34.</span><cite>Kim HR, Shim HS, Chung JH, et al. 
Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Cancer
2012;118:729-39. 10.1002/cncr.26311</cite> [<a href="https://doi.org/10.1002/cncr.26311" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21720997/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Distinct%20clinical%20features%20and%20outcomes%20in%20never-smokers%20with%20nonsmall%20cell%20lung%20cancer%20who%20harbor%20EGFR%20or%20KRAS%20mutations%20or%20ALK%20rearrangement.&amp;author=HR%20Kim&amp;author=HS%20Shim&amp;author=JH%20Chung&amp;volume=118&amp;publication_year=2012&amp;pages=729-39&amp;pmid=21720997&amp;doi=10.1002/cncr.26311&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r35">
<span class="label">35.</span><cite>Ha SY, Choi SJ, Cho JH, et al. 
Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR.
Oncotarget
2015;6:5465-74. 10.18632/oncotarget.2925</cite> [<a href="https://doi.org/10.18632/oncotarget.2925" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4467161/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25760072/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Lung%20cancer%20in%20never-smoker%20Asian%20females%20is%20driven%20by%20oncogenic%20mutations,%20most%20often%20involving%20EGFR.&amp;author=SY%20Ha&amp;author=SJ%20Choi&amp;author=JH%20Cho&amp;volume=6&amp;publication_year=2015&amp;pages=5465-74&amp;pmid=25760072&amp;doi=10.18632/oncotarget.2925&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r36">
<span class="label">36.</span><cite>Serizawa M, Koh Y, Kenmotsu H, et al. 
Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute study.
Cancer
2014;120:1471-81. 10.1002/cncr.28604</cite> [<a href="https://doi.org/10.1002/cncr.28604" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24700479/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Assessment%20of%20mutational%20profile%20of%20Japanese%20lung%20adenocarcinoma%20patients%20by%20multitarget%20assays:%20a%20prospective,%20single-institute%20study.&amp;author=M%20Serizawa&amp;author=Y%20Koh&amp;author=H%20Kenmotsu&amp;volume=120&amp;publication_year=2014&amp;pages=1471-81&amp;pmid=24700479&amp;doi=10.1002/cncr.28604&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r37">
<span class="label">37.</span><cite>Li S, Choi YL, Gong Z, et al. 
Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma.
J Thorac Oncol
2016;11:2129-40. 10.1016/j.jtho.2016.08.142</cite> [<a href="https://doi.org/10.1016/j.jtho.2016.08.142" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27615396/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Thorac%20Oncol&amp;title=Comprehensive%20Characterization%20of%20Oncogenic%20Drivers%20in%20Asian%20Lung%20Adenocarcinoma.&amp;author=S%20Li&amp;author=YL%20Choi&amp;author=Z%20Gong&amp;volume=11&amp;publication_year=2016&amp;pages=2129-40&amp;pmid=27615396&amp;doi=10.1016/j.jtho.2016.08.142&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r38">
<span class="label">38.</span><cite>Zheng D, Wang R, Ye T, et al. 
MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer.
Oncotarget
2016;7:41691-702. 10.18632/oncotarget.9541</cite> [<a href="https://doi.org/10.18632/oncotarget.9541" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5173088/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27223439/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=MET%20exon%2014%20skipping%20defines%20a%20unique%20molecular%20class%20of%20non-small%20cell%20lung%20cancer.&amp;author=D%20Zheng&amp;author=R%20Wang&amp;author=T%20Ye&amp;volume=7&amp;publication_year=2016&amp;pages=41691-702&amp;pmid=27223439&amp;doi=10.18632/oncotarget.9541&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r39">
<span class="label">39.</span><cite>Gou LY, Niu FY, Wu YL, et al. 
Differences in driver genes between smoking-related and non-smoking-related lung cancer in the Chinese population.
Cancer
2015;121
Suppl 17:3069-79. 10.1002/cncr.29531</cite> [<a href="https://doi.org/10.1002/cncr.29531" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26331813/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Differences%20in%20driver%20genes%20between%20smoking-related%20and%20non-smoking-related%20lung%20cancer%20in%20the%20Chinese%20population.&amp;author=LY%20Gou&amp;author=FY%20Niu&amp;author=YL%20Wu&amp;volume=121&amp;issue=Suppl%2017&amp;publication_year=2015&amp;pages=3069-79&amp;pmid=26331813&amp;doi=10.1002/cncr.29531&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r40">
<span class="label">40.</span><cite>An SJ, Chen ZH, Su J, et al. 
Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.
PLoS One
2012;7:e40109. 10.1371/journal.pone.0040109</cite> [<a href="https://doi.org/10.1371/journal.pone.0040109" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3387024/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22768234/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20One&amp;title=Identification%20of%20enriched%20driver%20gene%20alterations%20in%20subgroups%20of%20non-small%20cell%20lung%20cancer%20patients%20based%20on%20histology%20and%20smoking%20status.&amp;author=SJ%20An&amp;author=ZH%20Chen&amp;author=J%20Su&amp;volume=7&amp;publication_year=2012&amp;pages=e40109&amp;pmid=22768234&amp;doi=10.1371/journal.pone.0040109&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r41">
<span class="label">41.</span><cite>Li H, Pan Y, Li Y, et al. 
Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Lung Cancer
2013;79:8-13. 10.1016/j.lungcan.2012.09.018</cite> [<a href="https://doi.org/10.1016/j.lungcan.2012.09.018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23098378/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung%20Cancer&amp;title=Frequency%20of%20well-identified%20oncogenic%20driver%20mutations%20in%20lung%20adenocarcinoma%20of%20smokers%20varies%20with%20histological%20subtypes%20and%20graduated%20smoking%20dose.&amp;author=H%20Li&amp;author=Y%20Pan&amp;author=Y%20Li&amp;volume=79&amp;publication_year=2013&amp;pages=8-13&amp;pmid=23098378&amp;doi=10.1016/j.lungcan.2012.09.018&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r42">
<span class="label">42.</span><cite>Lynch TJ, Bell DW, Sordella R, et al. 
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
N Engl J Med
2004;350:2129-39. 10.1056/NEJMoa040938</cite> [<a href="https://doi.org/10.1056/NEJMoa040938" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15118073/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Activating%20mutations%20in%20the%20epidermal%20growth%20factor%20receptor%20underlying%20responsiveness%20of%20non-small-cell%20lung%20cancer%20to%20gefitinib.&amp;author=TJ%20Lynch&amp;author=DW%20Bell&amp;author=R%20Sordella&amp;volume=350&amp;publication_year=2004&amp;pages=2129-39&amp;pmid=15118073&amp;doi=10.1056/NEJMoa040938&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r43">
<span class="label">43.</span><cite>Pao W, Miller V, Zakowski M, et al. 
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
Proc Natl Acad Sci U S A
2004;101:13306-11. 10.1073/pnas.0405220101</cite> [<a href="https://doi.org/10.1073/pnas.0405220101" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC516528/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15329413/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&amp;title=EGF%20receptor%20gene%20mutations%20are%20common%20in%20lung%20cancers%20from%20%22never%20smokers%22%20and%20are%20associated%20with%20sensitivity%20of%20tumors%20to%20gefitinib%20and%20erlotinib.&amp;author=W%20Pao&amp;author=V%20Miller&amp;author=M%20Zakowski&amp;volume=101&amp;publication_year=2004&amp;pages=13306-11&amp;pmid=15329413&amp;doi=10.1073/pnas.0405220101&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r44">
<span class="label">44.</span><cite>Paez JG, Janne PA, Lee JC, et al. 
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Science
2004;304:1497-500. 10.1126/science.1099314</cite> [<a href="https://doi.org/10.1126/science.1099314" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15118125/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=EGFR%20mutations%20in%20lung%20cancer:%20correlation%20with%20clinical%20response%20to%20gefitinib%20therapy.&amp;author=JG%20Paez&amp;author=PA%20Janne&amp;author=JC%20Lee&amp;volume=304&amp;publication_year=2004&amp;pages=1497-500&amp;pmid=15118125&amp;doi=10.1126/science.1099314&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r45">
<span class="label">45.</span><cite>Wu YL, Zhou C, Hu CP, et al. 
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Lancet Oncol
2014;15:213-22. 10.1016/S1470-2045(13)70604-1</cite> [<a href="https://doi.org/10.1016/S1470-2045(13)70604-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24439929/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&amp;title=Afatinib%20versus%20cisplatin%20plus%20gemcitabine%20for%20first-line%20treatment%20of%20Asian%20patients%20with%20advanced%20non-small-cell%20lung%20cancer%20harbouring%20EGFR%20mutations%20(LUX-Lung%206):%20an%20open-label,%20randomised%20phase%203%20trial.&amp;author=YL%20Wu&amp;author=C%20Zhou&amp;author=CP%20Hu&amp;volume=15&amp;publication_year=2014&amp;pages=213-22&amp;pmid=24439929&amp;doi=10.1016/S1470-2045(13)70604-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r46">
<span class="label">46.</span><cite>Mok TS, Wu YL, Thongprasert S, et al. 
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
N Engl J Med
2009;361:947-57. 10.1056/NEJMoa0810699</cite> [<a href="https://doi.org/10.1056/NEJMoa0810699" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19692680/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Gefitinib%20or%20carboplatin-paclitaxel%20in%20pulmonary%20adenocarcinoma.&amp;author=TS%20Mok&amp;author=YL%20Wu&amp;author=S%20Thongprasert&amp;volume=361&amp;publication_year=2009&amp;pages=947-57&amp;pmid=19692680&amp;doi=10.1056/NEJMoa0810699&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r47">
<span class="label">47.</span><cite>Han JY, Park K, Kim SW, et al. 
First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.
J Clin Oncol
2012;30:1122-8. 10.1200/JCO.2011.36.8456</cite> [<a href="https://doi.org/10.1200/JCO.2011.36.8456" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22370314/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=First-SIGNAL:%20first-line%20single-agent%20iressa%20versus%20gemcitabine%20and%20cisplatin%20trial%20in%20never-smokers%20with%20adenocarcinoma%20of%20the%20lung.&amp;author=JY%20Han&amp;author=K%20Park&amp;author=SW%20Kim&amp;volume=30&amp;publication_year=2012&amp;pages=1122-8&amp;pmid=22370314&amp;doi=10.1200/JCO.2011.36.8456&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r48">
<span class="label">48.</span><cite>Wu YL, Zhou C, Liam CK, et al. 
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.
Ann Oncol
2015;26:1883-9. 10.1093/annonc/mdv270</cite> [<a href="https://doi.org/10.1093/annonc/mdv270" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26105600/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol&amp;title=First-line%20erlotinib%20versus%20gemcitabine/cisplatin%20in%20patients%20with%20advanced%20EGFR%20mutation-positive%20non-small-cell%20lung%20cancer:%20analyses%20from%20the%20phase%20III,%20randomized,%20open-label,%20ENSURE%20study.&amp;author=YL%20Wu&amp;author=C%20Zhou&amp;author=CK%20Liam&amp;volume=26&amp;publication_year=2015&amp;pages=1883-9&amp;pmid=26105600&amp;doi=10.1093/annonc/mdv270&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r49">
<span class="label">49.</span><cite>Zhou C, Wu YL, Chen G, et al. 
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Lancet Oncol
2011;12:735-42. 10.1016/S1470-2045(11)70184-X</cite> [<a href="https://doi.org/10.1016/S1470-2045(11)70184-X" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21783417/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&amp;title=Erlotinib%20versus%20chemotherapy%20as%20first-line%20treatment%20for%20patients%20with%20advanced%20EGFR%20mutation-positive%20non-small-cell%20lung%20cancer%20(OPTIMAL,%20CTONG-0802):%20a%20multicentre,%20open-label,%20randomised,%20phase%203%20study.&amp;author=C%20Zhou&amp;author=YL%20Wu&amp;author=G%20Chen&amp;volume=12&amp;publication_year=2011&amp;pages=735-42&amp;pmid=21783417&amp;doi=10.1016/S1470-2045(11)70184-X&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r50">
<span class="label">50.</span><cite>Shi YK, Wang L, Han BH, et al. 
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.
Ann Oncol
2017;28:2443-50. 10.1093/annonc/mdx359</cite> [<a href="https://doi.org/10.1093/annonc/mdx359" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28945850/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol&amp;title=First-line%20icotinib%20versus%20cisplatin/pemetrexed%20plus%20pemetrexed%20maintenance%20therapy%20for%20patients%20with%20advanced%20EGFR%20mutation-positive%20lung%20adenocarcinoma%20(CONVINCE):%20a%20phase%203,%20open-label,%20randomized%20study.&amp;author=YK%20Shi&amp;author=L%20Wang&amp;author=BH%20Han&amp;volume=28&amp;publication_year=2017&amp;pages=2443-50&amp;pmid=28945850&amp;doi=10.1093/annonc/mdx359&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r51">
<span class="label">51.</span><cite>Mitsudomi T, Morita S, Yatabe Y, et al. 
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
Lancet Oncol
2010;11:121-8. 10.1016/S1470-2045(09)70364-X</cite> [<a href="https://doi.org/10.1016/S1470-2045(09)70364-X" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20022809/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&amp;title=Gefitinib%20versus%20cisplatin%20plus%20docetaxel%20in%20patients%20with%20non-small-cell%20lung%20cancer%20harbouring%20mutations%20of%20the%20epidermal%20growth%20factor%20receptor%20(WJTOG3405):%20an%20open%20label,%20randomised%20phase%203%20trial.&amp;author=T%20Mitsudomi&amp;author=S%20Morita&amp;author=Y%20Yatabe&amp;volume=11&amp;publication_year=2010&amp;pages=121-8&amp;pmid=20022809&amp;doi=10.1016/S1470-2045(09)70364-X&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r52">
<span class="label">52.</span><cite>Maemondo M, Inoue A, Kobayashi K, et al. 
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
N Engl J Med
2010;362:2380-8. 10.1056/NEJMoa0909530</cite> [<a href="https://doi.org/10.1056/NEJMoa0909530" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20573926/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Gefitinib%20or%20chemotherapy%20for%20non-small-cell%20lung%20cancer%20with%20mutated%20EGFR.&amp;author=M%20Maemondo&amp;author=A%20Inoue&amp;author=K%20Kobayashi&amp;volume=362&amp;publication_year=2010&amp;pages=2380-8&amp;pmid=20573926&amp;doi=10.1056/NEJMoa0909530&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r53">
<span class="label">53.</span><cite>Lee CK, Wu YL, Ding PN, et al. 
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.
J Clin Oncol
2015;33:1958-65. 10.1200/JCO.2014.58.1736</cite> [<a href="https://doi.org/10.1200/JCO.2014.58.1736" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25897154/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Impact%20of%20Specific%20Epidermal%20Growth%20Factor%20Receptor%20(EGFR)%20Mutations%20and%20Clinical%20Characteristics%20on%20Outcomes%20After%20Treatment%20With%20EGFR%20Tyrosine%20Kinase%20Inhibitors%20Versus%20Chemotherapy%20in%20EGFR-Mutant%20Lung%20Cancer:%20A%20Meta-Analysis.&amp;author=CK%20Lee&amp;author=YL%20Wu&amp;author=PN%20Ding&amp;volume=33&amp;publication_year=2015&amp;pages=1958-65&amp;pmid=25897154&amp;doi=10.1200/JCO.2014.58.1736&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r54">
<span class="label">54.</span><cite>Park K, Yu CJ, Kim SW, et al. 
First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.
JAMA Oncol
2016;2:305-12. 10.1001/jamaoncol.2015.4921</cite> [<a href="https://doi.org/10.1001/jamaoncol.2015.4921" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26720423/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Oncol&amp;title=First-Line%20Erlotinib%20Therapy%20Until%20and%20Beyond%20Response%20Evaluation%20Criteria%20in%20Solid%20Tumors%20Progression%20in%20Asian%20Patients%20With%20Epidermal%20Growth%20Factor%20Receptor%20Mutation-Positive%20Non-Small-Cell%20Lung%20Cancer:%20The%20ASPIRATION%20Study.&amp;author=K%20Park&amp;author=CJ%20Yu&amp;author=SW%20Kim&amp;volume=2&amp;publication_year=2016&amp;pages=305-12&amp;pmid=26720423&amp;doi=10.1001/jamaoncol.2015.4921&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r55">
<span class="label">55.</span><cite>Schuler M, Yang JC, Park K, et al. 
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Ann Oncol
2016;27:417-23. 10.1093/annonc/mdv597</cite> [<a href="https://doi.org/10.1093/annonc/mdv597" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4769992/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26646759/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol&amp;title=Afatinib%20beyond%20progression%20in%20patients%20with%20non-small-cell%20lung%20cancer%20following%20chemotherapy,%20erlotinib/gefitinib%20and%20afatinib:%20phase%20III%20randomized%20LUX-Lung%205%20trial.&amp;author=M%20Schuler&amp;author=JC%20Yang&amp;author=K%20Park&amp;volume=27&amp;publication_year=2016&amp;pages=417-23&amp;pmid=26646759&amp;doi=10.1093/annonc/mdv597&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r56">
<span class="label">56.</span><cite>Soria JC, Wu YL, Nakagawa K, et al. 
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Lancet Oncol
2015;16:990-8. 10.1016/S1470-2045(15)00121-7</cite> [<a href="https://doi.org/10.1016/S1470-2045(15)00121-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26159065/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&amp;title=Gefitinib%20plus%20chemotherapy%20versus%20placebo%20plus%20chemotherapy%20in%20EGFR-mutation-positive%20non-small-cell%20lung%20cancer%20after%20progression%20on%20first-line%20gefitinib%20(IMPRESS):%20a%20phase%203%20randomised%20trial.&amp;author=JC%20Soria&amp;author=YL%20Wu&amp;author=K%20Nakagawa&amp;volume=16&amp;publication_year=2015&amp;pages=990-8&amp;pmid=26159065&amp;doi=10.1016/S1470-2045(15)00121-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r57">
<span class="label">57.</span><cite>Mok TSK, Kim SW, Wu YL, et al. 
Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.
J Clin Oncol
2017;35:4027-34. 10.1200/JCO.2017.73.9250</cite> [<a href="https://doi.org/10.1200/JCO.2017.73.9250" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28968167/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Gefitinib%20Plus%20Chemotherapy%20Versus%20Chemotherapy%20in%20Epidermal%20Growth%20Factor%20Receptor%20Mutation-Positive%20Non-Small-Cell%20Lung%20Cancer%20Resistant%20to%20First-Line%20Gefitinib%20(IMPRESS):%20Overall%20Survival%20and%20Biomarker%20Analyses.&amp;author=TSK%20Mok&amp;author=SW%20Kim&amp;author=YL%20Wu&amp;volume=35&amp;publication_year=2017&amp;pages=4027-34&amp;pmid=28968167&amp;doi=10.1200/JCO.2017.73.9250&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r58">
<span class="label">58.</span><cite>Ding T, Zhou F, Chen X, et al. 
Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations.
J Thorac Dis
2017;9:2923-34. 10.21037/jtd.2017.07.107</cite> [<a href="https://doi.org/10.21037/jtd.2017.07.107" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5708402/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29221264/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Thorac%20Dis&amp;title=Continuation%20of%20gefitinib%20plus%20chemotherapy%20prolongs%20progression-free%20survival%20in%20advanced%20non-small%20cell%20lung%20cancer%20patients%20who%20get%20acquired%20resistance%20to%20gefitinib%20without%20T790M%20mutations.&amp;author=T%20Ding&amp;author=F%20Zhou&amp;author=X%20Chen&amp;volume=9&amp;publication_year=2017&amp;pages=2923-34&amp;pmid=29221264&amp;doi=10.21037/jtd.2017.07.107&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r59">
<span class="label">59.</span><cite>Kuiper JL, Heideman DA, Thunnissen E, et al. 
Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
Lung Cancer
2014;85:19-24. 10.1016/j.lungcan.2014.03.016</cite> [<a href="https://doi.org/10.1016/j.lungcan.2014.03.016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24768581/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung%20Cancer&amp;title=Incidence%20of%20T790M%20mutation%20in%20(sequential)%20rebiopsies%20in%20EGFR-mutated%20NSCLC-patients.&amp;author=JL%20Kuiper&amp;author=DA%20Heideman&amp;author=E%20Thunnissen&amp;volume=85&amp;publication_year=2014&amp;pages=19-24&amp;pmid=24768581&amp;doi=10.1016/j.lungcan.2014.03.016&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r60">
<span class="label">60.</span><cite>Li W, Ren S, Li J, et al. 
T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.
Lung Cancer
2014;84:295-300. 10.1016/j.lungcan.2014.03.011</cite> [<a href="https://doi.org/10.1016/j.lungcan.2014.03.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24685306/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung%20Cancer&amp;title=T790M%20mutation%20is%20associated%20with%20better%20efficacy%20of%20treatment%20beyond%20progression%20with%20EGFR-TKI%20in%20advanced%20NSCLC%20patients.&amp;author=W%20Li&amp;author=S%20Ren&amp;author=J%20Li&amp;volume=84&amp;publication_year=2014&amp;pages=295-300&amp;pmid=24685306&amp;doi=10.1016/j.lungcan.2014.03.011&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r61">
<span class="label">61.</span><cite>Nosaki K, Satouchi M, Kurata T, et al. 
Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study.
Lung Cancer
2016;101:1-8. 10.1016/j.lungcan.2016.07.007</cite> [<a href="https://doi.org/10.1016/j.lungcan.2016.07.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27794396/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung%20Cancer&amp;title=Re-biopsy%20status%20among%20non-small%20cell%20lung%20cancer%20patients%20in%20Japan:%20A%20retrospective%20study.&amp;author=K%20Nosaki&amp;author=M%20Satouchi&amp;author=T%20Kurata&amp;volume=101&amp;publication_year=2016&amp;pages=1-8&amp;pmid=27794396&amp;doi=10.1016/j.lungcan.2016.07.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r62">
<span class="label">62.</span><cite>Wu SG, Liu YN, Tsai MF, et al. 
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.
Oncotarget
2016;7:12404-13.</cite> [<a href="https://doi.org/10.18632/oncotarget.7189" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4914294/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26862733/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=The%20mechanism%20of%20acquired%20resistance%20to%20irreversible%20EGFR%20tyrosine%20kinase%20inhibitor-afatinib%20in%20lung%20adenocarcinoma%20patients.&amp;author=SG%20Wu&amp;author=YN%20Liu&amp;author=MF%20Tsai&amp;volume=7&amp;publication_year=2016&amp;pages=12404-13&amp;pmid=26862733&amp;doi=10.18632/oncotarget.7189&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r63">
<span class="label">63.</span><cite>Janne PA, Yang JC, Kim DW, et al. 
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
N Engl J Med
2015;372:1689-99. 10.1056/NEJMoa1411817</cite> [<a href="https://doi.org/10.1056/NEJMoa1411817" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25923549/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=AZD9291%20in%20EGFR%20inhibitor-resistant%20non-small-cell%20lung%20cancer.&amp;author=PA%20Janne&amp;author=JC%20Yang&amp;author=DW%20Kim&amp;volume=372&amp;publication_year=2015&amp;pages=1689-99&amp;pmid=25923549&amp;doi=10.1056/NEJMoa1411817&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r64">
<span class="label">64.</span><cite>Yang JC, Ahn MJ, Kim DW, et al. 
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
J Clin Oncol
2017;35:1288-96. 10.1200/JCO.2016.70.3223</cite> [<a href="https://doi.org/10.1200/JCO.2016.70.3223" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28221867/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Osimertinib%20in%20Pretreated%20T790M-Positive%20Advanced%20Non-Small-Cell%20Lung%20Cancer:%20AURA%20Study%20Phase%20II%20Extension%20Component.&amp;author=JC%20Yang&amp;author=MJ%20Ahn&amp;author=DW%20Kim&amp;volume=35&amp;publication_year=2017&amp;pages=1288-96&amp;pmid=28221867&amp;doi=10.1200/JCO.2016.70.3223&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r65">
<span class="label">65.</span><cite>Goss G, Tsai CM, Shepherd FA, et al. 
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
Lancet Oncol
2016;17:1643-52. 10.1016/S1470-2045(16)30508-3</cite> [<a href="https://doi.org/10.1016/S1470-2045(16)30508-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27751847/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&amp;title=Osimertinib%20for%20pretreated%20EGFR%20Thr790Met-positive%20advanced%20non-small-cell%20lung%20cancer%20(AURA2):%20a%20multicentre,%20open-label,%20single-arm,%20phase%202%20study.&amp;author=G%20Goss&amp;author=CM%20Tsai&amp;author=FA%20Shepherd&amp;volume=17&amp;publication_year=2016&amp;pages=1643-52&amp;pmid=27751847&amp;doi=10.1016/S1470-2045(16)30508-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r66">
<span class="label">66.</span><cite>Mok TS, Wu YL, Ahn MJ, et al. 
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
N Engl J Med
2017;376:629-40. 10.1056/NEJMoa1612674</cite> [<a href="https://doi.org/10.1056/NEJMoa1612674" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6762027/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27959700/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Osimertinib%20or%20Platinum-Pemetrexed%20in%20EGFR%20T790M-Positive%20Lung%20Cancer.&amp;author=TS%20Mok&amp;author=YL%20Wu&amp;author=MJ%20Ahn&amp;volume=376&amp;publication_year=2017&amp;pages=629-40&amp;pmid=27959700&amp;doi=10.1056/NEJMoa1612674&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r67">
<span class="label">67.</span><cite>Zhou C, Wang M, Cheng Y, et al. 
Osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced NSCLC: Updated Phase II study results including progression-free survival (PFS).
Ann Oncol
2017;1354P
abtract.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol&amp;title=Osimertinib%20in%20Asia-Pacific%20patients%20(pts)%20with%20EGFR%20T790M-positive%20advanced%20NSCLC:%20Updated%20Phase%20II%20study%20results%20including%20progression-free%20survival%20(PFS).&amp;author=C%20Zhou&amp;author=M%20Wang&amp;author=Y%20Cheng&amp;publication_year=2017&amp;pages=1354P&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r68">
<span class="label">68.</span><cite>Soda M, Choi YL, Enomoto M, et al. 
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Nature
2007;448:561-6. 10.1038/nature05945</cite> [<a href="https://doi.org/10.1038/nature05945" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17625570/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Identification%20of%20the%20transforming%20EML4-ALK%20fusion%20gene%20in%20non-small-cell%20lung%20cancer.&amp;author=M%20Soda&amp;author=YL%20Choi&amp;author=M%20Enomoto&amp;volume=448&amp;publication_year=2007&amp;pages=561-6&amp;pmid=17625570&amp;doi=10.1038/nature05945&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r69">
<span class="label">69.</span><cite>Pan Y, Zhang Y, Li Y, et al. 
ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Lung Cancer
2014;84:121-6. 10.1016/j.lungcan.2014.02.007</cite> [<a href="https://doi.org/10.1016/j.lungcan.2014.02.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24629636/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung%20Cancer&amp;title=ALK,%20ROS1%20and%20RET%20fusions%20in%201139%20lung%20adenocarcinomas:%20a%20comprehensive%20study%20of%20common%20and%20fusion%20pattern-specific%20clinicopathologic,%20histologic%20and%20cytologic%20features.&amp;author=Y%20Pan&amp;author=Y%20Zhang&amp;author=Y%20Li&amp;volume=84&amp;publication_year=2014&amp;pages=121-6&amp;pmid=24629636&amp;doi=10.1016/j.lungcan.2014.02.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r70">
<span class="label">70.</span><cite>Solomon BJ, Mok T, Kim DW, et al. 
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
N Engl J Med
2014;371:2167-77. 10.1056/NEJMoa1408440</cite> [<a href="https://doi.org/10.1056/NEJMoa1408440" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25470694/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=First-line%20crizotinib%20versus%20chemotherapy%20in%20ALK-positive%20lung%20cancer.&amp;author=BJ%20Solomon&amp;author=T%20Mok&amp;author=DW%20Kim&amp;volume=371&amp;publication_year=2014&amp;pages=2167-77&amp;pmid=25470694&amp;doi=10.1056/NEJMoa1408440&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r71">
<span class="label">71.</span><cite>Nishio M, Kim DW, Wu YL, et al. 
Crizotinib Versus Chemotherapy in Asian Patients with Advanced ALK-positive Non-small Cell Lung Cancer.
Cancer Res Treat
2018;50:691-700. </cite> [<a href="https://doi.org/10.4143/crt.2017.280" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6056984/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28701030/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res%20Treat&amp;title=Crizotinib%20Versus%20Chemotherapy%20in%20Asian%20Patients%20with%20Advanced%20ALK-positive%20Non-small%20Cell%20Lung%20Cancer.&amp;author=M%20Nishio&amp;author=DW%20Kim&amp;author=YL%20Wu&amp;volume=50&amp;publication_year=2018&amp;pages=691-700&amp;pmid=28701030&amp;doi=10.4143/crt.2017.280&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r72">
<span class="label">72.</span><cite>Lu S, Mok T, Lu Y, et al. 
Phase 3 study of first-line crizotinib vs pemetrexedcisplatin/carboplatin (PCC) in East Asian patients with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC).
J Clin Oncol
2016;34:9058.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Phase%203%20study%20of%20first-line%20crizotinib%20vs%20pemetrexedcisplatin/carboplatin%20(PCC)%20in%20East%20Asian%20patients%20with%20ALK+%20advanced%20non-squamous%20non-small%20cell%20lung%20cancer%20(NSCLC).&amp;author=S%20Lu&amp;author=T%20Mok&amp;author=Y%20Lu&amp;volume=34&amp;publication_year=2016&amp;pages=9058&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r73">
<span class="label">73.</span><cite>Gadgeel SM, Gandhi L, Riely GJ, et al. 
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Lancet Oncol
2014;15:1119-28. 10.1016/S1470-2045(14)70362-6</cite> [<a href="https://doi.org/10.1016/S1470-2045(14)70362-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25153538/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&amp;title=Safety%20and%20activity%20of%20alectinib%20against%20systemic%20disease%20and%20brain%20metastases%20in%20patients%20with%20crizotinib-resistant%20ALK-rearranged%20non-small-cell%20lung%20cancer%20(AF-002JG):%20results%20from%20the%20dose-finding%20portion%20of%20a%20phase%201/2%20study.&amp;author=SM%20Gadgeel&amp;author=L%20Gandhi&amp;author=GJ%20Riely&amp;volume=15&amp;publication_year=2014&amp;pages=1119-28&amp;pmid=25153538&amp;doi=10.1016/S1470-2045(14)70362-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r74">
<span class="label">74.</span><cite>Kodama T, Tsukaguchi T, Yoshida M, et al. 
Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.
Cancer Lett
2014;351:215-21. 10.1016/j.canlet.2014.05.020</cite> [<a href="https://doi.org/10.1016/j.canlet.2014.05.020" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24887559/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Lett&amp;title=Selective%20ALK%20inhibitor%20alectinib%20with%20potent%20antitumor%20activity%20in%20models%20of%20crizotinib%20resistance.&amp;author=T%20Kodama&amp;author=T%20Tsukaguchi&amp;author=M%20Yoshida&amp;volume=351&amp;publication_year=2014&amp;pages=215-21&amp;pmid=24887559&amp;doi=10.1016/j.canlet.2014.05.020&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r75">
<span class="label">75.</span><cite>Seto T, Kiura K, Nishio M, et al. 
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.
Lancet Oncol
2013;14:590-8. 10.1016/S1470-2045(13)70142-6</cite> [<a href="https://doi.org/10.1016/S1470-2045(13)70142-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23639470/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&amp;title=CH5424802%20(RO5424802)%20for%20patients%20with%20ALK-rearranged%20advanced%20non-small-cell%20lung%20cancer%20(AF-001JP%20study):%20a%20single-arm,%20open-label,%20phase%201-2%20study.&amp;author=T%20Seto&amp;author=K%20Kiura&amp;author=M%20Nishio&amp;volume=14&amp;publication_year=2013&amp;pages=590-8&amp;pmid=23639470&amp;doi=10.1016/S1470-2045(13)70142-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r76">
<span class="label">76.</span><cite>Hida T, Nokihara H, Kondo M, et al. 
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Lancet
2017;390:29-39. 10.1016/S0140-6736(17)30565-2</cite> [<a href="https://doi.org/10.1016/S0140-6736(17)30565-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28501140/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Alectinib%20versus%20crizotinib%20in%20patients%20with%20ALK-positive%20non-small-cell%20lung%20cancer%20(J-ALEX):%20an%20open-label,%20randomised%20phase%203%20trial.&amp;author=T%20Hida&amp;author=H%20Nokihara&amp;author=M%20Kondo&amp;volume=390&amp;publication_year=2017&amp;pages=29-39&amp;pmid=28501140&amp;doi=10.1016/S0140-6736(17)30565-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r77">
<span class="label">77.</span><cite>Peters S, Camidge DR, Shaw AT, et al. 
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
2017;377:829-38. 10.1056/NEJMoa1704795</cite> [<a href="https://doi.org/10.1056/NEJMoa1704795" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28586279/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Alectinib%20versus%20Crizotinib%20in%20Untreated%20ALK-Positive%20Non-Small-Cell%20Lung%20Cancer.&amp;author=S%20Peters&amp;author=DR%20Camidge&amp;author=AT%20Shaw&amp;volume=377&amp;publication_year=2017&amp;pages=829-38&amp;pmid=28586279&amp;doi=10.1056/NEJMoa1704795&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r78">
<span class="label">78.</span><cite>Rikova K, Guo A, Zeng Q, et al. 
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
Cell
2007;131:1190-203. 10.1016/j.cell.2007.11.025</cite> [<a href="https://doi.org/10.1016/j.cell.2007.11.025" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18083107/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Global%20survey%20of%20phosphotyrosine%20signaling%20identifies%20oncogenic%20kinases%20in%20lung%20cancer.&amp;author=K%20Rikova&amp;author=A%20Guo&amp;author=Q%20Zeng&amp;volume=131&amp;publication_year=2007&amp;pages=1190-203&amp;pmid=18083107&amp;doi=10.1016/j.cell.2007.11.025&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r79">
<span class="label">79.</span><cite>Bergethon K, Shaw AT, Ou SH, et al. 
ROS1 rearrangements define a unique molecular class of lung cancers.
J Clin Oncol
2012;30:863-70. 10.1200/JCO.2011.35.6345</cite> [<a href="https://doi.org/10.1200/JCO.2011.35.6345" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3295572/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22215748/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=ROS1%20rearrangements%20define%20a%20unique%20molecular%20class%20of%20lung%20cancers.&amp;author=K%20Bergethon&amp;author=AT%20Shaw&amp;author=SH%20Ou&amp;volume=30&amp;publication_year=2012&amp;pages=863-70&amp;pmid=22215748&amp;doi=10.1200/JCO.2011.35.6345&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r80">
<span class="label">80.</span><cite>Davies KD, Le AT, Theodoro MF, et al. 
Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.
Clin Cancer Res
2012;18:4570-9. 10.1158/1078-0432.CCR-12-0550</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-12-0550" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3703205/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22919003/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Identifying%20and%20targeting%20ROS1%20gene%20fusions%20in%20non-small%20cell%20lung%20cancer.&amp;author=KD%20Davies&amp;author=AT%20Le&amp;author=MF%20Theodoro&amp;volume=18&amp;publication_year=2012&amp;pages=4570-9&amp;pmid=22919003&amp;doi=10.1158/1078-0432.CCR-12-0550&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r81">
<span class="label">81.</span><cite>Yoshida A, Kohno T, Tsuta K, et al. 
ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases.
Am J Surg Pathol
2013;37:554-62. 10.1097/PAS.0b013e3182758fe6</cite> [<a href="https://doi.org/10.1097/PAS.0b013e3182758fe6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23426121/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Surg%20Pathol&amp;title=ROS1-rearranged%20lung%20cancer:%20a%20clinicopathologic%20and%20molecular%20study%20of%2015%20surgical%20cases.&amp;author=A%20Yoshida&amp;author=T%20Kohno&amp;author=K%20Tsuta&amp;volume=37&amp;publication_year=2013&amp;pages=554-62&amp;pmid=23426121&amp;doi=10.1097/PAS.0b013e3182758fe6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r82">
<span class="label">82.</span><cite>Cai W, Li X, Su C, et al. 
ROS1 fusions in Chinese patients with non-small-cell lung cancer.
Ann Oncol
2013;24:1822-7. 10.1093/annonc/mdt071</cite> [<a href="https://doi.org/10.1093/annonc/mdt071" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23514723/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol&amp;title=ROS1%20fusions%20in%20Chinese%20patients%20with%20non-small-cell%20lung%20cancer.&amp;author=W%20Cai&amp;author=X%20Li&amp;author=C%20Su&amp;volume=24&amp;publication_year=2013&amp;pages=1822-7&amp;pmid=23514723&amp;doi=10.1093/annonc/mdt071&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r83">
<span class="label">83.</span><cite>Suehara Y, Arcila M, Wang L, et al. 
Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.
Clin Cancer Res
2012;18:6599-608. 10.1158/1078-0432.CCR-12-0838</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-12-0838" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4234119/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23052255/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Identification%20of%20KIF5B-RET%20and%20GOPC-ROS1%20fusions%20in%20lung%20adenocarcinomas%20through%20a%20comprehensive%20mRNA-based%20screen%20for%20tyrosine%20kinase%20fusions.&amp;author=Y%20Suehara&amp;author=M%20Arcila&amp;author=L%20Wang&amp;volume=18&amp;publication_year=2012&amp;pages=6599-608&amp;pmid=23052255&amp;doi=10.1158/1078-0432.CCR-12-0838&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r84">
<span class="label">84.</span><cite>Rimkunas VM, Crosby KE, Li D, et al. 
Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
Clin Cancer Res
2012;18:4449-57. 10.1158/1078-0432.CCR-11-3351</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-11-3351" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22661537/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Analysis%20of%20receptor%20tyrosine%20kinase%20ROS1-positive%20tumors%20in%20non-small%20cell%20lung%20cancer:%20identification%20of%20a%20FIG-ROS1%20fusion.&amp;author=VM%20Rimkunas&amp;author=KE%20Crosby&amp;author=D%20Li&amp;volume=18&amp;publication_year=2012&amp;pages=4449-57&amp;pmid=22661537&amp;doi=10.1158/1078-0432.CCR-11-3351&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r85">
<span class="label">85.</span><cite>Shaw AT, Ou SH, Bang YJ, et al. 
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
N Engl J Med
2014;371:1963-71. 10.1056/NEJMoa1406766</cite> [<a href="https://doi.org/10.1056/NEJMoa1406766" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4264527/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25264305/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Crizotinib%20in%20ROS1-rearranged%20non-small-cell%20lung%20cancer.&amp;author=AT%20Shaw&amp;author=SH%20Ou&amp;author=YJ%20Bang&amp;volume=371&amp;publication_year=2014&amp;pages=1963-71&amp;pmid=25264305&amp;doi=10.1056/NEJMoa1406766&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r86">
<span class="label">86.</span><cite>Lim SM, Kim HR, Lee JS, et al. 
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.
J Clin Oncol
2017;35:2613-8. 10.1200/JCO.2016.71.3701</cite> [<a href="https://doi.org/10.1200/JCO.2016.71.3701" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28520527/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Open-Label,%20Multicenter,%20Phase%20II%20Study%20of%20Ceritinib%20in%20Patients%20With%20Non-Small-Cell%20Lung%20Cancer%20Harboring%20ROS1%20Rearrangement.&amp;author=SM%20Lim&amp;author=HR%20Kim&amp;author=JS%20Lee&amp;volume=35&amp;publication_year=2017&amp;pages=2613-8&amp;pmid=28520527&amp;doi=10.1200/JCO.2016.71.3701&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r87">
<span class="label">87.</span><cite>Shaw AT, Felip E, Bauer TM, et al. 
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Lancet Oncol
2017;18:1590-9. 10.1016/S1470-2045(17)30680-0</cite> [<a href="https://doi.org/10.1016/S1470-2045(17)30680-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5777233/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29074098/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&amp;title=Lorlatinib%20in%20non-small-cell%20lung%20cancer%20with%20ALK%20or%20ROS1%20rearrangement:%20an%20international,%20multicentre,%20open-label,%20single-arm%20first-in-man%20phase%201%20trial.&amp;author=AT%20Shaw&amp;author=E%20Felip&amp;author=TM%20Bauer&amp;volume=18&amp;publication_year=2017&amp;pages=1590-9&amp;pmid=29074098&amp;doi=10.1016/S1470-2045(17)30680-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r88">
<span class="label">88.</span><cite>Drilon A, Siena S, Ou SI, et al. 
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Cancer Discov
2017;7:400-9. 10.1158/2159-8290.CD-16-1237</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-16-1237" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5380583/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28183697/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Discov&amp;title=Safety%20and%20Antitumor%20Activity%20of%20the%20Multitargeted%20Pan-TRK,%20ROS1,%20and%20ALK%20Inhibitor%20Entrectinib:%20Combined%20Results%20from%20Two%20Phase%20I%20Trials%20(ALKA-372-001%20and%20STARTRK-1).&amp;author=A%20Drilon&amp;author=S%20Siena&amp;author=SI%20Ou&amp;volume=7&amp;publication_year=2017&amp;pages=400-9&amp;pmid=28183697&amp;doi=10.1158/2159-8290.CD-16-1237&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r89">
<span class="label">89.</span><cite>Chong CR, Bahcall M, Capelletti M, et al. 
Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.
Clin Cancer Res
2017;23:204-13. 10.1158/1078-0432.CCR-15-1601</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-15-1601" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5203969/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27370605/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Identification%20of%20Existing%20Drugs%20That%20Effectively%20Target%20NTRK1%20and%20ROS1%20Rearrangements%20in%20Lung%20Cancer.&amp;author=CR%20Chong&amp;author=M%20Bahcall&amp;author=M%20Capelletti&amp;volume=23&amp;publication_year=2017&amp;pages=204-13&amp;pmid=27370605&amp;doi=10.1158/1078-0432.CCR-15-1601&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r90">
<span class="label">90.</span><cite>Goto K, Yang JC, Kim DW, et al. 
Phase II study of crizotinib in East Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).
J Clin Oncol
2016;34:9022.</cite> [<a href="https://doi.org/10.1200/JCO.2017.75.5587" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29596029/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Phase%20II%20study%20of%20crizotinib%20in%20East%20Asian%20patients%20(pts)%20with%20ROS1-positive%20advanced%20non-small%20cell%20lung%20cancer%20(NSCLC).&amp;author=K%20Goto&amp;author=JC%20Yang&amp;author=DW%20Kim&amp;volume=34&amp;publication_year=2016&amp;pages=9022&amp;pmid=29596029&amp;doi=10.1200/JCO.2017.75.5587&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r91">
<span class="label">91.</span><cite>Wang R, Hu H, Pan Y, et al. 
RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.
J Clin Oncol
2012;30:4352-9. 10.1200/JCO.2012.44.1477</cite> [<a href="https://doi.org/10.1200/JCO.2012.44.1477" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23150706/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=RET%20fusions%20define%20a%20unique%20molecular%20and%20clinicopathologic%20subtype%20of%20non-small-cell%20lung%20cancer.&amp;author=R%20Wang&amp;author=H%20Hu&amp;author=Y%20Pan&amp;volume=30&amp;publication_year=2012&amp;pages=4352-9&amp;pmid=23150706&amp;doi=10.1200/JCO.2012.44.1477&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r92">
<span class="label">92.</span><cite>Cai W, Su C, Li X, et al. 
KIF5B-RET fusions in Chinese patients with non-small cell lung cancer.
Cancer
2013;119:1486-94. 10.1002/cncr.27940</cite> [<a href="https://doi.org/10.1002/cncr.27940" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23378251/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=KIF5B-RET%20fusions%20in%20Chinese%20patients%20with%20non-small%20cell%20lung%20cancer.&amp;author=W%20Cai&amp;author=C%20Su&amp;author=X%20Li&amp;volume=119&amp;publication_year=2013&amp;pages=1486-94&amp;pmid=23378251&amp;doi=10.1002/cncr.27940&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r93">
<span class="label">93.</span><cite>Drilon A, Rekhtman N, Arcila M, et al. 
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
Lancet Oncol
2016;17:1653-60. 10.1016/S1470-2045(16)30562-9</cite> [<a href="https://doi.org/10.1016/S1470-2045(16)30562-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5143197/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27825636/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&amp;title=Cabozantinib%20in%20patients%20with%20advanced%20RET-rearranged%20non-small-cell%20lung%20cancer:%20an%20open-label,%20single-centre,%20phase%202,%20single-arm%20trial.&amp;author=A%20Drilon&amp;author=N%20Rekhtman&amp;author=M%20Arcila&amp;volume=17&amp;publication_year=2016&amp;pages=1653-60&amp;pmid=27825636&amp;doi=10.1016/S1470-2045(16)30562-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r94">
<span class="label">94.</span><cite>Yoh K, Seto T, Satouchi M, et al. 
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.
Lancet Respir Med
2017;5:42-50. 10.1016/S2213-2600(16)30322-8</cite> [<a href="https://doi.org/10.1016/S2213-2600(16)30322-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27825616/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Respir%20Med&amp;title=Vandetanib%20in%20patients%20with%20previously%20treated%20RET-rearranged%20advanced%20non-small-cell%20lung%20cancer%20(LURET):%20an%20open-label,%20multicentre%20phase%202%20trial.&amp;author=K%20Yoh&amp;author=T%20Seto&amp;author=M%20Satouchi&amp;volume=5&amp;publication_year=2017&amp;pages=42-50&amp;pmid=27825616&amp;doi=10.1016/S2213-2600(16)30322-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r95">
<span class="label">95.</span><cite>Drilon A, Wang L, Hasanovic A, et al. 
Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.
Cancer Discov
2013;3:630-5. 10.1158/2159-8290.CD-13-0035</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-13-0035" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4160032/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23533264/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Discov&amp;title=Response%20to%20Cabozantinib%20in%20patients%20with%20RET%20fusion-positive%20lung%20adenocarcinomas.&amp;author=A%20Drilon&amp;author=L%20Wang&amp;author=A%20Hasanovic&amp;volume=3&amp;publication_year=2013&amp;pages=630-5&amp;pmid=23533264&amp;doi=10.1158/2159-8290.CD-13-0035&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r96">
<span class="label">96.</span><cite>Gautschi O, Milia J, Filleron T, et al. 
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
J Clin Oncol
2017;35:1403-10. 10.1200/JCO.2016.70.9352</cite> [<a href="https://doi.org/10.1200/JCO.2016.70.9352" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5559893/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28447912/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Targeting%20RET%20in%20Patients%20With%20RET-Rearranged%20Lung%20Cancers:%20Results%20From%20the%20Global,%20Multicenter%20RET%20Registry.&amp;author=O%20Gautschi&amp;author=J%20Milia&amp;author=T%20Filleron&amp;volume=35&amp;publication_year=2017&amp;pages=1403-10&amp;pmid=28447912&amp;doi=10.1200/JCO.2016.70.9352&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r97">
<span class="label">97.</span><cite>Frampton GM, Ali SM, Rosenzweig M, et al. 
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
Cancer Discov
2015;5:850-9. 10.1158/2159-8290.CD-15-0285</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-15-0285" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25971938/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Discov&amp;title=Activation%20of%20MET%20via%20diverse%20exon%2014%20splicing%20alterations%20occurs%20in%20multiple%20tumor%20types%20and%20confers%20clinical%20sensitivity%20to%20MET%20inhibitors.&amp;author=GM%20Frampton&amp;author=SM%20Ali&amp;author=M%20Rosenzweig&amp;volume=5&amp;publication_year=2015&amp;pages=850-9&amp;pmid=25971938&amp;doi=10.1158/2159-8290.CD-15-0285&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r98">
<span class="label">98.</span><cite>Awad MM, Oxnard GR, Jackman DM, et al. 
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
J Clin Oncol
2016;34:721-30. 10.1200/JCO.2015.63.4600</cite> [<a href="https://doi.org/10.1200/JCO.2015.63.4600" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26729443/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=MET%20Exon%2014%20Mutations%20in%20Non-Small-Cell%20Lung%20Cancer%20Are%20Associated%20With%20Advanced%20Age%20and%20Stage-Dependent%20MET%20Genomic%20Amplification%20and%20c-Met%20Overexpression.&amp;author=MM%20Awad&amp;author=GR%20Oxnard&amp;author=DM%20Jackman&amp;volume=34&amp;publication_year=2016&amp;pages=721-30&amp;pmid=26729443&amp;doi=10.1200/JCO.2015.63.4600&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r99">
<span class="label">99.</span><cite>Lee GD, Lee SE, Oh DY, et al. 
MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values.
J Thorac Oncol
2017;12:1233-46. 10.1016/j.jtho.2017.04.031</cite> [<a href="https://doi.org/10.1016/j.jtho.2017.04.031" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28502721/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Thorac%20Oncol&amp;title=MET%20Exon%2014%20Skipping%20Mutations%20in%20Lung%20Adenocarcinoma:%20Clinicopathologic%20Implications%20and%20Prognostic%20Values.&amp;author=GD%20Lee&amp;author=SE%20Lee&amp;author=DY%20Oh&amp;volume=12&amp;publication_year=2017&amp;pages=1233-46&amp;pmid=28502721&amp;doi=10.1016/j.jtho.2017.04.031&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r100">
<span class="label">100.</span><cite>Liu SY, Gou LY, Li AN, et al. 
The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC.
J Thorac Oncol
2016;11:1503-10. 10.1016/j.jtho.2016.05.016</cite> [<a href="https://doi.org/10.1016/j.jtho.2016.05.016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27257131/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Thorac%20Oncol&amp;title=The%20Unique%20Characteristics%20of%20MET%20Exon%2014%20Mutation%20in%20Chinese%20Patients%20with%20NSCLC.&amp;author=SY%20Liu&amp;author=LY%20Gou&amp;author=AN%20Li&amp;volume=11&amp;publication_year=2016&amp;pages=1503-10&amp;pmid=27257131&amp;doi=10.1016/j.jtho.2016.05.016&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r101">
<span class="label">101.</span><cite>Jorge SE, Schulman S, Freed JA, et al. 
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.
Lung Cancer
2015;90:369-74. 10.1016/j.lungcan.2015.10.028</cite> [<a href="https://doi.org/10.1016/j.lungcan.2015.10.028" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4724060/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26791794/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung%20Cancer&amp;title=Responses%20to%20the%20multitargeted%20MET/ALK/ROS1%20inhibitor%20crizotinib%20and%20co-occurring%20mutations%20in%20lung%20adenocarcinomas%20with%20MET%20amplification%20or%20MET%20exon%2014%20skipping%20mutation.&amp;author=SE%20Jorge&amp;author=S%20Schulman&amp;author=JA%20Freed&amp;volume=90&amp;publication_year=2015&amp;pages=369-74&amp;pmid=26791794&amp;doi=10.1016/j.lungcan.2015.10.028&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r102">
<span class="label">102.</span><cite>Shigematsu H, Takahashi T, Nomura M, et al. 
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
Cancer Res
2005;65:1642-6. 10.1158/0008-5472.CAN-04-4235</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-04-4235" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15753357/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=Somatic%20mutations%20of%20the%20HER2%20kinase%20domain%20in%20lung%20adenocarcinomas.&amp;author=H%20Shigematsu&amp;author=T%20Takahashi&amp;author=M%20Nomura&amp;volume=65&amp;publication_year=2005&amp;pages=1642-6&amp;pmid=15753357&amp;doi=10.1158/0008-5472.CAN-04-4235&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r103">
<span class="label">103.</span><cite>Song Z, Yu X, Shi Z, et al. 
HER2 mutations in Chinese patients with non-small cell lung cancer.
Oncotarget
2016;7:78152-8. 10.18632/oncotarget.11313</cite> [<a href="https://doi.org/10.18632/oncotarget.11313" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5363651/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27825109/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=HER2%20mutations%20in%20Chinese%20patients%20with%20non-small%20cell%20lung%20cancer.&amp;author=Z%20Song&amp;author=X%20Yu&amp;author=Z%20Shi&amp;volume=7&amp;publication_year=2016&amp;pages=78152-8&amp;pmid=27825109&amp;doi=10.18632/oncotarget.11313&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r104">
<span class="label">104.</span><cite>Shan L, Qiu T, Ling Y, et al. 
Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma.
PLoS One
2015;10:e0130447. 10.1371/journal.pone.0130447</cite> [<a href="https://doi.org/10.1371/journal.pone.0130447" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4477932/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26102513/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20One&amp;title=Prevalence%20and%20Clinicopathological%20Characteristics%20of%20HER2%20and%20BRAF%20Mutation%20in%20Chinese%20Patients%20with%20Lung%20Adenocarcinoma.&amp;author=L%20Shan&amp;author=T%20Qiu&amp;author=Y%20Ling&amp;volume=10&amp;publication_year=2015&amp;pages=e0130447&amp;pmid=26102513&amp;doi=10.1371/journal.pone.0130447&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r105">
<span class="label">105.</span><cite>Li X, Zhao C, Su C, et al. 
Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China.
BMC Cancer
2016;16:828. 10.1186/s12885-016-2875-z</cite> [<a href="https://doi.org/10.1186/s12885-016-2875-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5084329/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27793199/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Cancer&amp;title=Epidemiological%20study%20of%20HER-2%20mutations%20among%20EGFR%20wild-type%20lung%20adenocarcinoma%20patients%20in%20China.&amp;author=X%20Li&amp;author=C%20Zhao&amp;author=C%20Su&amp;volume=16&amp;publication_year=2016&amp;pages=828&amp;pmid=27793199&amp;doi=10.1186/s12885-016-2875-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r106">
<span class="label">106.</span><cite>Mazieres J, Peters S, Lepage B, et al. 
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
J Clin Oncol
2013;31:1997-2003. 10.1200/JCO.2012.45.6095</cite> [<a href="https://doi.org/10.1200/JCO.2012.45.6095" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23610105/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Lung%20cancer%20that%20harbors%20an%20HER2%20mutation:%20epidemiologic%20characteristics%20and%20therapeutic%20perspectives.&amp;author=J%20Mazieres&amp;author=S%20Peters&amp;author=B%20Lepage&amp;volume=31&amp;publication_year=2013&amp;pages=1997-2003&amp;pmid=23610105&amp;doi=10.1200/JCO.2012.45.6095&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r107">
<span class="label">107.</span><cite>Eng J, Hsu M, Chaft JE, et al. 
Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.
Lung Cancer
2016;99:53-6. 10.1016/j.lungcan.2016.05.030</cite> [<a href="https://doi.org/10.1016/j.lungcan.2016.05.030" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5305295/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27565914/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung%20Cancer&amp;title=Outcomes%20of%20chemotherapies%20and%20HER2%20directed%20therapies%20in%20advanced%20HER2-mutant%20lung%20cancers.&amp;author=J%20Eng&amp;author=M%20Hsu&amp;author=JE%20Chaft&amp;volume=99&amp;publication_year=2016&amp;pages=53-6&amp;pmid=27565914&amp;doi=10.1016/j.lungcan.2016.05.030&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r108">
<span class="label">108.</span><cite>De Greve J, Teugels E, Geers C, et al. 
Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.
Lung Cancer
2012;76:123-7. 10.1016/j.lungcan.2012.01.008</cite> [<a href="https://doi.org/10.1016/j.lungcan.2012.01.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22325357/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung%20Cancer&amp;title=Clinical%20activity%20of%20afatinib%20(BIBW%202992)%20in%20patients%20with%20lung%20adenocarcinoma%20with%20mutations%20in%20the%20kinase%20domain%20of%20HER2/neu.&amp;author=J%20De%20Greve&amp;author=E%20Teugels&amp;author=C%20Geers&amp;volume=76&amp;publication_year=2012&amp;pages=123-7&amp;pmid=22325357&amp;doi=10.1016/j.lungcan.2012.01.008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r109">
<span class="label">109.</span><cite>Gandhi L, Bahleda R, Tolaney SM, et al. 
Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
J Clin Oncol
2014;32:68-75. 10.1200/JCO.2012.47.2787</cite> [<a href="https://doi.org/10.1200/JCO.2012.47.2787" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24323026/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Phase%20I%20study%20of%20neratinib%20in%20combination%20with%20temsirolimus%20in%20patients%20with%20human%20epidermal%20growth%20factor%20receptor%202-dependent%20and%20other%20solid%20tumors.&amp;author=L%20Gandhi&amp;author=R%20Bahleda&amp;author=SM%20Tolaney&amp;volume=32&amp;publication_year=2014&amp;pages=68-75&amp;pmid=24323026&amp;doi=10.1200/JCO.2012.47.2787&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r110">
<span class="label">110.</span><cite>Kris MG, Camidge DR, Giaccone G, et al. 
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.
Ann Oncol
2015;26:1421-7. 10.1093/annonc/mdv186</cite> [<a href="https://doi.org/10.1093/annonc/mdv186" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5006511/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25899785/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol&amp;title=Targeting%20HER2%20aberrations%20as%20actionable%20drivers%20in%20lung%20cancers:%20phase%20II%20trial%20of%20the%20pan-HER%20tyrosine%20kinase%20inhibitor%20dacomitinib%20in%20patients%20with%20HER2-mutant%20or%20amplified%20tumors.&amp;author=MG%20Kris&amp;author=DR%20Camidge&amp;author=G%20Giaccone&amp;volume=26&amp;publication_year=2015&amp;pages=1421-7&amp;pmid=25899785&amp;doi=10.1093/annonc/mdv186&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r111">
<span class="label">111.</span><cite>Li X, Yang C, Wan H, et al. 
Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer.
Eur J Pharm Sci
2017;110:51-61. 10.1016/j.ejps.2017.01.021</cite> [<a href="https://doi.org/10.1016/j.ejps.2017.01.021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28115222/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Pharm%20Sci&amp;title=Discovery%20and%20development%20of%20pyrotinib:%20A%20novel%20irreversible%20EGFR/HER2%20dual%20tyrosine%20kinase%20inhibitor%20with%20favorable%20safety%20profiles%20for%20the%20treatment%20of%20breast%20cancer.&amp;author=X%20Li&amp;author=C%20Yang&amp;author=H%20Wan&amp;volume=110&amp;publication_year=2017&amp;pages=51-61&amp;pmid=28115222&amp;doi=10.1016/j.ejps.2017.01.021&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r112">
<span class="label">112.</span><cite>Ma F, Li Q, Chen S, et al. 
Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
J Clin Oncol
2017;35:3105-12. 10.1200/JCO.2016.69.6179</cite> [<a href="https://doi.org/10.1200/JCO.2016.69.6179" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28498781/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Phase%20I%20Study%20and%20Biomarker%20Analysis%20of%20Pyrotinib,%20a%20Novel%20Irreversible%20Pan-ErbB%20Receptor%20Tyrosine%20Kinase%20Inhibitor,%20in%20Patients%20With%20Human%20Epidermal%20Growth%20Factor%20Receptor%202-Positive%20Metastatic%20Breast%20Cancer.&amp;author=F%20Ma&amp;author=Q%20Li&amp;author=S%20Chen&amp;volume=35&amp;publication_year=2017&amp;pages=3105-12&amp;pmid=28498781&amp;doi=10.1200/JCO.2016.69.6179&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r113">
<span class="label">113.</span><cite>Ren S, Zhou C, Gao G, et al. Preliminary results of a phase II study about the efficacy and safety of pyrotinib in patients with HER2 mutant advanced NSCLC. Journal of Thoracic Oncology 2016;12:MA04.3.</cite>
</li>
<li id="r114">
<span class="label">114.</span><cite>Huang Y, Wang R, Pan Y, et al. 
Clinical and genetic features of lung squamous cell cancer in never-smokers.
Oncotarget
2016;7:35979-88.</cite> [<a href="https://doi.org/10.18632/oncotarget.8745" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5094976/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27092882/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Clinical%20and%20genetic%20features%20of%20lung%20squamous%20cell%20cancer%20in%20never-smokers.&amp;author=Y%20Huang&amp;author=R%20Wang&amp;author=Y%20Pan&amp;volume=7&amp;publication_year=2016&amp;pages=35979-88&amp;pmid=27092882&amp;doi=10.18632/oncotarget.8745&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r115">
<span class="label">115.</span><cite>Lee HY, Lee SH, Won JK, et al. 
Analysis of Fifty Hotspot Mutations of Lung Squamous Cell Carcinoma in Never-smokers.
J Korean Med Sci
2017;32:415-20. 10.3346/jkms.2017.32.3.415</cite> [<a href="https://doi.org/10.3346/jkms.2017.32.3.415" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5290099/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28145643/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Korean%20Med%20Sci&amp;title=Analysis%20of%20Fifty%20Hotspot%20Mutations%20of%20Lung%20Squamous%20Cell%20Carcinoma%20in%20Never-smokers.&amp;author=HY%20Lee&amp;author=SH%20Lee&amp;author=JK%20Won&amp;volume=32&amp;publication_year=2017&amp;pages=415-20&amp;pmid=28145643&amp;doi=10.3346/jkms.2017.32.3.415&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r116">
<span class="label">116.</span><cite>Hata A, Katakami N, Yoshioka H, et al. 
How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?
J Thorac Oncol
2013;8:89-95. 10.1097/JTO.0b013e31827690b5</cite> [<a href="https://doi.org/10.1097/JTO.0b013e31827690b5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23242440/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Thorac%20Oncol&amp;title=How%20sensitive%20are%20epidermal%20growth%20factor%20receptor-tyrosine%20kinase%20inhibitors%20for%20squamous%20cell%20carcinoma%20of%20the%20lung%20harboring%20EGFR%20gene-sensitive%20mutations?&amp;author=A%20Hata&amp;author=N%20Katakami&amp;author=H%20Yoshioka&amp;volume=8&amp;publication_year=2013&amp;pages=89-95&amp;pmid=23242440&amp;doi=10.1097/JTO.0b013e31827690b5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r117">
<span class="label">117.</span><cite>Xu J, Zhang Y, Jin B, et al. 
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China.
J Cancer Res Clin Oncol
2016;142:1325-30. 10.1007/s00432-016-2133-4</cite> [<a href="https://doi.org/10.1007/s00432-016-2133-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26942444/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Cancer%20Res%20Clin%20Oncol&amp;title=Efficacy%20of%20EGFR%20tyrosine%20kinase%20inhibitors%20for%20non-adenocarcinoma%20lung%20cancer%20patients%20harboring%20EGFR-sensitizing%20mutations%20in%20China.&amp;author=J%20Xu&amp;author=Y%20Zhang&amp;author=B%20Jin&amp;volume=142&amp;publication_year=2016&amp;pages=1325-30&amp;pmid=26942444&amp;doi=10.1007/s00432-016-2133-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r118">
<span class="label">118.</span><cite>Wang Q, He Y, Yang X, et al. 
Extraordinary response to crizotinib in a woman with squamous cell lung cancer after two courses of failed chemotherapy.
BMC Pulm Med
2014;14:83. 10.1186/1471-2466-14-83</cite> [<a href="https://doi.org/10.1186/1471-2466-14-83" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4027997/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24885608/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Pulm%20Med&amp;title=Extraordinary%20response%20to%20crizotinib%20in%20a%20woman%20with%20squamous%20cell%20lung%20cancer%20after%20two%20courses%20of%20failed%20chemotherapy.&amp;author=Q%20Wang&amp;author=Y%20He&amp;author=X%20Yang&amp;volume=14&amp;publication_year=2014&amp;pages=83&amp;pmid=24885608&amp;doi=10.1186/1471-2466-14-83&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r119">
<span class="label">119.</span><cite>Zhang Q, Wang J, Zhang S.
ALK-rearranged squamous cell lung cancer: a case report.
Int J Clin Exp Pathol
2015;8:2195-8.</cite> [<a href="/articles/PMC4396204/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25973127/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Clin%20Exp%20Pathol&amp;title=ALK-rearranged%20squamous%20cell%20lung%20cancer:%20a%20case%20report.&amp;author=Q%20Zhang&amp;author=J%20Wang&amp;author=S.%20Zhang&amp;volume=8&amp;publication_year=2015&amp;pages=2195-8&amp;pmid=25973127&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r120">
<span class="label">120.</span><cite>Wang W, Song Z, Zhang Y.
Response to crizotinib in a squamous cell lung carcinoma patient harbouring echinoderm microtubule-associated protein-like 4-anaplastic lymphoma translocation: A case report.
Thorac Cancer
2016;7:355-7. 10.1111/1759-7714.12298</cite> [<a href="https://doi.org/10.1111/1759-7714.12298" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4846625/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27148422/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Thorac%20Cancer&amp;title=Response%20to%20crizotinib%20in%20a%20squamous%20cell%20lung%20carcinoma%20patient%20harbouring%20echinoderm%20microtubule-associated%20protein-like%204-anaplastic%20lymphoma%20translocation:%20A%20case%20report.&amp;author=W%20Wang&amp;author=Z%20Song&amp;author=Y%20Zhang&amp;volume=7&amp;publication_year=2016&amp;pages=355-7&amp;pmid=27148422&amp;doi=10.1111/1759-7714.12298&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r121">
<span class="label">121.</span><cite>Mamesaya N, Nakashima K, Naito T, et al. 
ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
BMC Cancer
2017;17:471. 10.1186/s12885-017-3468-1</cite> [<a href="https://doi.org/10.1186/s12885-017-3468-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5501098/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28683775/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Cancer&amp;title=ALK-rearranged%20lung%20squamous%20cell%20carcinoma%20responding%20to%20alectinib:%20a%20case%20report%20and%20review%20of%20the%20literature.&amp;author=N%20Mamesaya&amp;author=K%20Nakashima&amp;author=T%20Naito&amp;volume=17&amp;publication_year=2017&amp;pages=471&amp;pmid=28683775&amp;doi=10.1186/s12885-017-3468-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r122">
<span class="label">122.</span><cite>Li Q, Wu J, Yan LX, et al. 
ALK and ROS1 Double-Rearranged Lung Squamous Cell Carcinoma Responding to Crizotinib Treatment: A Case Report.
J Thorac Oncol
2017;12:e193-7. 10.1016/j.jtho.2017.08.021</cite> [<a href="https://doi.org/10.1016/j.jtho.2017.08.021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28911956/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Thorac%20Oncol&amp;title=ALK%20and%20ROS1%20Double-Rearranged%20Lung%20Squamous%20Cell%20Carcinoma%20Responding%20to%20Crizotinib%20Treatment:%20A%20Case%20Report.&amp;author=Q%20Li&amp;author=J%20Wu&amp;author=LX%20Yan&amp;volume=12&amp;publication_year=2017&amp;pages=e193-7&amp;pmid=28911956&amp;doi=10.1016/j.jtho.2017.08.021&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r123">
<span class="label">123.</span><cite>Tamiya A, Shimizu S, Atagi S.
A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib.
J Thorac Oncol
2015;10:e74. 10.1097/JTO.0000000000000575</cite> [<a href="https://doi.org/10.1097/JTO.0000000000000575" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26200283/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Thorac%20Oncol&amp;title=A%20Case%20of%20Squamous%20Cell%20Carcinoma%20Harboring%20an%20EML4-ALK%20Rearrangement%20that%20Was%20Unsuccessfully%20Treated%20with%20the%20ALK%20Inhibitor%20Alectinib.&amp;author=A%20Tamiya&amp;author=S%20Shimizu&amp;author=S.%20Atagi&amp;volume=10&amp;publication_year=2015&amp;pages=e74&amp;pmid=26200283&amp;doi=10.1097/JTO.0000000000000575&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r124">
<span class="label">124.</span><cite>Varghese AM, Zakowski MF, Yu HA, et al. 
Small-cell lung cancers in patients who never smoked cigarettes.
J Thorac Oncol
2014;9:892-6. 10.1097/JTO.0000000000000142</cite> [<a href="https://doi.org/10.1097/JTO.0000000000000142" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4199745/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24828667/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Thorac%20Oncol&amp;title=Small-cell%20lung%20cancers%20in%20patients%20who%20never%20smoked%20cigarettes.&amp;author=AM%20Varghese&amp;author=MF%20Zakowski&amp;author=HA%20Yu&amp;volume=9&amp;publication_year=2014&amp;pages=892-6&amp;pmid=24828667&amp;doi=10.1097/JTO.0000000000000142&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r125">
<span class="label">125.</span><cite>Ou SH, Ziogas A, Zell JA.
Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity.
J Thorac Oncol
2009;4:37-43. 10.1097/JTO.0b013e31819140fb</cite> [<a href="https://doi.org/10.1097/JTO.0b013e31819140fb" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19096304/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Thorac%20Oncol&amp;title=Prognostic%20factors%20for%20survival%20in%20extensive%20stage%20small%20cell%20lung%20cancer%20(ED-SCLC):%20the%20importance%20of%20smoking%20history,%20socioeconomic%20and%20marital%20statuses,%20and%20ethnicity.&amp;author=SH%20Ou&amp;author=A%20Ziogas&amp;author=JA%20Zell&amp;volume=4&amp;publication_year=2009&amp;pages=37-43&amp;pmid=19096304&amp;doi=10.1097/JTO.0b013e31819140fb&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r126">
<span class="label">126.</span><cite>Le X, Desai NV, Majid A, et al. 
De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors.
Lung Cancer
2015;88:70-3. 10.1016/j.lungcan.2015.02.003</cite> [<a href="https://doi.org/10.1016/j.lungcan.2015.02.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4355318/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25700797/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung%20Cancer&amp;title=De%20novo%20pulmonary%20small%20cell%20carcinomas%20and%20large%20cell%20neuroendocrine%20carcinomas%20harboring%20EGFR%20mutations:%20Lack%20of%20response%20to%20EGFR%20inhibitors.&amp;author=X%20Le&amp;author=NV%20Desai&amp;author=A%20Majid&amp;volume=88&amp;publication_year=2015&amp;pages=70-3&amp;pmid=25700797&amp;doi=10.1016/j.lungcan.2015.02.003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r127">
<span class="label">127.</span><cite>Morgensztern D, Herbst RS.
Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer.
Clin Cancer Res
2016;22:3713-7. 10.1158/1078-0432.CCR-15-2998</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-15-2998" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27252413/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Nivolumab%20and%20Pembrolizumab%20for%20Non-Small%20Cell%20Lung%20Cancer.&amp;author=D%20Morgensztern&amp;author=RS%20Herbst&amp;volume=22&amp;publication_year=2016&amp;pages=3713-7&amp;pmid=27252413&amp;doi=10.1158/1078-0432.CCR-15-2998&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r128">
<span class="label">128.</span><cite>Brahmer J, Reckamp KL, Baas P, et al. 
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
N Engl J Med
2015;373:123-35. 10.1056/NEJMoa1504627</cite> [<a href="https://doi.org/10.1056/NEJMoa1504627" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4681400/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26028407/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Nivolumab%20versus%20Docetaxel%20in%20Advanced%20Squamous-Cell%20Non-Small-Cell%20Lung%20Cancer.&amp;author=J%20Brahmer&amp;author=KL%20Reckamp&amp;author=P%20Baas&amp;volume=373&amp;publication_year=2015&amp;pages=123-35&amp;pmid=26028407&amp;doi=10.1056/NEJMoa1504627&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r129">
<span class="label">129.</span><cite>Borghaei H, Paz-Ares L, Horn L, et al. 
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
N Engl J Med
2015;373:1627-39. 10.1056/NEJMoa1507643</cite> [<a href="https://doi.org/10.1056/NEJMoa1507643" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5705936/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26412456/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Nivolumab%20versus%20Docetaxel%20in%20Advanced%20Nonsquamous%20Non-Small-Cell%20Lung%20Cancer.&amp;author=H%20Borghaei&amp;author=L%20Paz-Ares&amp;author=L%20Horn&amp;volume=373&amp;publication_year=2015&amp;pages=1627-39&amp;pmid=26412456&amp;doi=10.1056/NEJMoa1507643&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r130">
<span class="label">130.</span><cite>Herbst RS, Baas P, Kim DW, et al. 
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Lancet
2016;387:1540-50. 10.1016/S0140-6736(15)01281-7</cite> [<a href="https://doi.org/10.1016/S0140-6736(15)01281-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26712084/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Pembrolizumab%20versus%20docetaxel%20for%20previously%20treated,%20PD-L1-positive,%20advanced%20non-small-cell%20lung%20cancer%20(KEYNOTE-010):%20a%20randomised%20controlled%20trial.&amp;author=RS%20Herbst&amp;author=P%20Baas&amp;author=DW%20Kim&amp;volume=387&amp;publication_year=2016&amp;pages=1540-50&amp;pmid=26712084&amp;doi=10.1016/S0140-6736(15)01281-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r131">
<span class="label">131.</span><cite>Fehrenbacher L, Spira A, Ballinger M, et al. 
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Lancet
2016;387:1837-46. 10.1016/S0140-6736(16)00587-0</cite> [<a href="https://doi.org/10.1016/S0140-6736(16)00587-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26970723/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Atezolizumab%20versus%20docetaxel%20for%20patients%20with%20previously%20treated%20non-small-cell%20lung%20cancer%20(POPLAR):%20a%20multicentre,%20open-label,%20phase%202%20randomised%20controlled%20trial.&amp;author=L%20Fehrenbacher&amp;author=A%20Spira&amp;author=M%20Ballinger&amp;volume=387&amp;publication_year=2016&amp;pages=1837-46&amp;pmid=26970723&amp;doi=10.1016/S0140-6736(16)00587-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r132">
<span class="label">132.</span><cite>Rittmeyer A, Barlesi F, Waterkamp D, et al. 
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Lancet
2017;389:255-65. 10.1016/S0140-6736(16)32517-X</cite> [<a href="https://doi.org/10.1016/S0140-6736(16)32517-X" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6886121/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27979383/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Atezolizumab%20versus%20docetaxel%20in%20patients%20with%20previously%20treated%20non-small-cell%20lung%20cancer%20(OAK):%20a%20phase%203,%20open-label,%20multicentre%20randomised%20controlled%20trial.&amp;author=A%20Rittmeyer&amp;author=F%20Barlesi&amp;author=D%20Waterkamp&amp;volume=389&amp;publication_year=2017&amp;pages=255-65&amp;pmid=27979383&amp;doi=10.1016/S0140-6736(16)32517-X&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r133">
<span class="label">133.</span><cite>Reck M, Rodriguez-Abreu D, Robinson AG, et al. 
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
2016;375:1823-33. 10.1056/NEJMoa1606774</cite> [<a href="https://doi.org/10.1056/NEJMoa1606774" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27718847/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Pembrolizumab%20versus%20Chemotherapy%20for%20PD-L1-Positive%20Non-Small-Cell%20Lung%20Cancer.&amp;author=M%20Reck&amp;author=D%20Rodriguez-Abreu&amp;author=AG%20Robinson&amp;volume=375&amp;publication_year=2016&amp;pages=1823-33&amp;pmid=27718847&amp;doi=10.1056/NEJMoa1606774&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r134">
<span class="label">134.</span><cite>Rizvi NA, Hellmann MD, Snyder A, et al. 
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Science
2015;348:124-8. 10.1126/science.aaa1348</cite> [<a href="https://doi.org/10.1126/science.aaa1348" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4993154/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25765070/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Cancer%20immunology.%20Mutational%20landscape%20determines%20sensitivity%20to%20PD-1%20blockade%20in%20non-small%20cell%20lung%20cancer.&amp;author=NA%20Rizvi&amp;author=MD%20Hellmann&amp;author=A%20Snyder&amp;volume=348&amp;publication_year=2015&amp;pages=124-8&amp;pmid=25765070&amp;doi=10.1126/science.aaa1348&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r135">
<span class="label">135.</span><cite>Carbone DP, Reck M, Paz-Ares L, et al. 
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
N Engl J Med
2017;376:2415-26. 10.1056/NEJMoa1613493</cite> [<a href="https://doi.org/10.1056/NEJMoa1613493" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6487310/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28636851/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=First-Line%20Nivolumab%20in%20Stage%20IV%20or%20Recurrent%20Non-Small-Cell%20Lung%20Cancer.&amp;author=DP%20Carbone&amp;author=M%20Reck&amp;author=L%20Paz-Ares&amp;volume=376&amp;publication_year=2017&amp;pages=2415-26&amp;pmid=28636851&amp;doi=10.1056/NEJMoa1613493&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r136">
<span class="label">136.</span><cite>Kinoshita T, Kudo-Saito C, Muramatsu R, et al. 
Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
Eur J Cancer
2017;86:15-27. 10.1016/j.ejca.2017.08.026</cite> [<a href="https://doi.org/10.1016/j.ejca.2017.08.026" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28950145/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Cancer&amp;title=Determination%20of%20poor%20prognostic%20immune%20features%20of%20tumour%20microenvironment%20in%20non-smoking%20patients%20with%20lung%20adenocarcinoma.&amp;author=T%20Kinoshita&amp;author=C%20Kudo-Saito&amp;author=R%20Muramatsu&amp;volume=86&amp;publication_year=2017&amp;pages=15-27&amp;pmid=28950145&amp;doi=10.1016/j.ejca.2017.08.026&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r137">
<span class="label">137.</span><cite>Lee CK, Man J, Lord S, et al. 
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.
JAMA Oncol
2018;4:210-216. 10.1001/jamaoncol.2017.4427</cite> [<a href="https://doi.org/10.1001/jamaoncol.2017.4427" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5838598/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29270615/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Oncol&amp;title=Clinical%20and%20Molecular%20Characteristics%20Associated%20With%20Survival%20Among%20Patients%20Treated%20With%20Checkpoint%20Inhibitors%20for%20Advanced%20Non-Small%20Cell%20Lung%20Carcinoma:%20A%20Systematic%20Review%20and%20Meta-analysis.&amp;author=CK%20Lee&amp;author=J%20Man&amp;author=S%20Lord&amp;volume=4&amp;publication_year=2018&amp;pages=210-216&amp;pmid=29270615&amp;doi=10.1001/jamaoncol.2017.4427&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r138">
<span class="label">138.</span><cite>Lee CK, Man J, Lord S, et al. 
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.
J Thorac Oncol
2017;12:403-7. 10.1016/j.jtho.2016.10.007</cite> [<a href="https://doi.org/10.1016/j.jtho.2016.10.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27765535/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Thorac%20Oncol&amp;title=Checkpoint%20Inhibitors%20in%20Metastatic%20EGFR-Mutated%20Non-Small%20Cell%20Lung%20Cancer-A%20Meta-Analysis.&amp;author=CK%20Lee&amp;author=J%20Man&amp;author=S%20Lord&amp;volume=12&amp;publication_year=2017&amp;pages=403-7&amp;pmid=27765535&amp;doi=10.1016/j.jtho.2016.10.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r139">
<span class="label">139.</span><cite>Gainor JF, Shaw AT, Sequist LV, et al. 
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
Clin Cancer Res
2016;22:4585-93. 10.1158/1078-0432.CCR-15-3101</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-15-3101" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5026567/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27225694/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=EGFR%20Mutations%20and%20ALK%20Rearrangements%20Are%20Associated%20with%20Low%20Response%20Rates%20to%20PD-1%20Pathway%20Blockade%20in%20Non-Small%20Cell%20Lung%20Cancer:%20A%20Retrospective%20Analysis.&amp;author=JF%20Gainor&amp;author=AT%20Shaw&amp;author=LV%20Sequist&amp;volume=22&amp;publication_year=2016&amp;pages=4585-93&amp;pmid=27225694&amp;doi=10.1158/1078-0432.CCR-15-3101&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r140">
<span class="label">140.</span><cite>Dong ZY, Zhang JT, Liu SY, et al. 
EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer.
Oncoimmunology
2017;6:e1356145. 10.1080/2162402X.2017.1356145</cite> [<a href="https://doi.org/10.1080/2162402X.2017.1356145" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5674946/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29147605/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncoimmunology&amp;title=EGFR%20mutation%20correlates%20with%20uninflamed%20phenotype%20and%20weak%20immunogenicity,%20causing%20impaired%20response%20to%20PD-1%20blockade%20in%20non-small%20cell%20lung%20cancer.&amp;author=ZY%20Dong&amp;author=JT%20Zhang&amp;author=SY%20Liu&amp;volume=6&amp;publication_year=2017&amp;pages=e1356145&amp;pmid=29147605&amp;doi=10.1080/2162402X.2017.1356145&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r141">
<span class="label">141.</span><cite>Streicher K, Higgs BW, Wu S, et al. 
Increased CD73 and reduced IFNG signature expression in relation to response rates to anti-PD-1(L1) therapies in EGFR-mutant NSCLC.
J Clin Oncol
2017;35:11505.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Increased%20CD73%20and%20reduced%20IFNG%20signature%20expression%20in%20relation%20to%20response%20rates%20to%20anti-PD-1(L1)%20therapies%20in%20EGFR-mutant%20NSCLC.&amp;author=K%20Streicher&amp;author=BW%20Higgs&amp;author=S%20Wu&amp;volume=35&amp;publication_year=2017&amp;pages=11505&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r142">
<span class="label">142.</span><cite>Sabari JK, Montecalvo J, Chen R, et al. 
PD-L1 expression and response to immunotherapy in patients with MET exon 14-altered non-small cell lung cancers (NSCLC).
J Clin Oncol
2017;35:8512.</cite> [<a href="https://doi.org/10.1093/annonc/mdy334" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6225900/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30165371/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=PD-L1%20expression%20and%20response%20to%20immunotherapy%20in%20patients%20with%20MET%20exon%2014-altered%20non-small%20cell%20lung%20cancers%20(NSCLC).&amp;author=JK%20Sabari&amp;author=J%20Montecalvo&amp;author=R%20Chen&amp;volume=35&amp;publication_year=2017&amp;pages=8512&amp;pmid=30165371&amp;doi=10.1093/annonc/mdy334&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r143">
<span class="label">143.</span><cite>Zhang Y, Wang Q, Han ZG, et al. 
Differences in epidermal growth factor receptor gene mutations and relationship with clinicopathological features in NSCLC between Uygur and Han ethnic groups.
Asian Pac J Cancer Prev
2013;14:2879-83. 10.7314/APJCP.2013.14.5.2879</cite> [<a href="https://doi.org/10.7314/APJCP.2013.14.5.2879" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23803047/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Asian%20Pac%20J%20Cancer%20Prev&amp;title=Differences%20in%20epidermal%20growth%20factor%20receptor%20gene%20mutations%20and%20relationship%20with%20clinicopathological%20features%20in%20NSCLC%20between%20Uygur%20and%20Han%20ethnic%20groups.&amp;author=Y%20Zhang&amp;author=Q%20Wang&amp;author=ZG%20Han&amp;volume=14&amp;publication_year=2013&amp;pages=2879-83&amp;pmid=23803047&amp;doi=10.7314/APJCP.2013.14.5.2879&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Translational Lung Cancer Research are provided here courtesy of <strong>AME Publications</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.21037/tlcr.2018.05.14"
                             class="usa-button usa-button--outline width-24 font-xs usa-link--external padding-left-0 padding-right-0"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <span class="height-3 display-inline-flex flex-align-center">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/tlcr-07-04-450.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (617.2 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/6131183/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/6131183/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC6131183%2F%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC6131183/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC6131183/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC6131183/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/30225210/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC6131183/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/30225210/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC6131183/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/6131183/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="ioO49pJSI4pkCsQ4kfBB1jdxifZ5rQXn3wSzdRXeGlPUetPyp8PwyL54eoFdZ2RB">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Web Policies

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    FOIA

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS Vulnerability Disclosure

    
</a>

                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Help

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Accessibility

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Careers

    
</a>

                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NLM

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NIH

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    USA.gov

    
</a>

                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>



        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
     <script src="https://code.jquery.com/jquery-3.5.0.min.js"
          integrity="sha256-xNzN2a4ltkB44Mc/Jz3pT4iU1cmeR0FkXs4pru/JxaQ="
          crossorigin="anonymous">
    </script>
    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-9bea7450.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-722d91a2.js"></script>
    
    

    </body>
</html>
